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ABSTRACT 
 
Synthesis, Characterization, and Toxicity Studies of Dirhodium and Diiridium 
Metal-Metal Bonded Anticancer Compounds. (August 2012) 
Sarah Margaret Lane, B.S., Bridgewater State University 
Chair of Advisory Committee: Dr. Kim R. Dunbar 
 
The anticancer properties of dirhodium tetraacetate were discovered in 
the 1970’s, and subsequently motivated the research of several dirhodium 
paddlewheel derivatives.  The promising results of this research led the Dunbar 
group to investigate the biological properties of dirhodium partial paddlewheel 
compounds.  Previous work in our group has focused on dirhodium carboxylate 
derivatives with a series of diimine ligands, namely 1,10-phenanthroline (phen), 
dipyrido[3,2-f:2',3'-h]quinoxaline (dpq), dipyrido[3,2a:2´,3´c] phenazine (dppz), 
and benzo[i]dipyrido[3,2-a:2',3'-c]phenazine) (dppn).  Current research has 
expanded this diimine series by substituting the carobxylate bridging group with 
p-methoxyphenylphosphine (PMP).  This new series of compounds was 
characterized by several techniques, including: X-Ray crystallography, 1H NMR 
spectroscopy, and electronic absorption spectroscopy.   
The cytotoxicity of these compounds towards HeLa cells was investigated 
in presence and absence of light in an effort to investigate the ability to use 
these compounds as photodynamic therapy (PDT) agents.  Cytotoxicity 
iv 
 
 
 
measurements were carried out using the 3-(4,5-dimethylthiazol-2-yl)-2,5 
diphenyltetrazolium bromide (MTT) assay.  It was found that in the dark 
[Rh2(PMP)2(dppz)2][BF4]2 (the dppz derivative of the dirhodium PMP compound) 
had no cytotoxicity towards HeLa cells, but experienced a 7 fold increase in 
cytotoxicity upon irradiation (with λirr equal to 350 nm).  This dramatic increase in 
cytotoxicity upon irradiation makes this compound a potential PDT agent.     
Diiridium (II,II) compounds were prepared in a dual attempt to determine 
how the properties of the dirhodium core effect the biological activities of these 
compounds, as well as investigate the biological activity of a set of compounds 
that has yet to be explored.  The compound [Ir2(DTolF)2(CH3CN)6][BF4]2 was 
chosen because it has a well understood dirhodium analogue, and it is a known 
compound.  However, it was discovered that there was a potential silver 
contamination in the final product, stemming from the silver trifluoroacetate 
oxidant used during synthesis.  Consequently, a new method of preparing this 
compound was required.  The new synthetic pathway for the diiridium compound 
[Ir2(DTolF)2(CH3CN)6][BF4]2 was devised, and the cytotoxicity and 
photocytotoxicity studies were performed for the first time (to our knowledge) on 
a diiridium (II,II) compound.  Despite the stability of the compound, it was 
determined to be highly toxic, both in the dark and upon irradiation.   
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CHAPTER I 
INTRODUCTION: 
CANCER AND CHEMOTHERAPY 
 
Cancer 
 A Definition 
Cancer is one of the most common causes of death in the United States; 
second only to heart disease1.  The statistics of this disease are daunting – 
analysis from 2010 reported statistics of 1 in 2 men, and 1 in 3 women will have, 
or die, from cancer.  This same report states that 1 in 8 women will be 
diagnosed with breast cancer.  In the year 2010 there were 1,529,560 million 
cases of cancer diagnosed in the US, and 569,490 deaths predicted for the year 
20102.  It is tantamount to first understand what cancer is in order to develop a 
rational strategy to combat this threat. 
Cancer is a disease where abnormal cells divide uncontrollably and can 
invade other tissue.  It is classified based on the type of tissue affected:  
adenocarcinoma (glandular tissue), blastoma (embryonic tissue), carcinoma 
(epithelial tissue), leukemia (tissues that form blood), lymphoma (lymphatic 
tissue), myeloma (bone marrow), and sarcoma (connective or supportive tissue 
– bone, cartilage, muscle).  The extent to which the disease has spread is 
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indicated in stages that range from I to IV, with IV being the most severe.  When 
staging cancer, the size of the tumor, the number of lymph nodes to which it has 
spread to, and how many organs to which it has metastasized are considered 
(known as the TNM classification system)2.   
While cancer is a current focus in modern scientific research, it is a 
problem that has existed for centuries.  There have been several breakthroughs 
in methods of treatment since the first recorded cases of cancer.  And while 
medicine has made drastic leaps since the time of ancient Egypt, there is much 
progress to be made.  In order to put the course of treatments into perspective 
one must go back to the beginning and retrace the course of cancer treatments. 
 
Ancient Egypt to Modern Day 
Cancer first got its name from Hippocrates – the father of western 
medicine3.  While Hippocrates may have been the first to name this disease, 
cancer had been known to exist for much longer.  The first evidence of the 
disease includes the abnormal bone growths seen on some ancient Egyptian 
mummies.  The first known text on cancer also dates back to ancient Egypt.  
The Edwin Smith Papyrus describes the ancient Egyptians attempt to cauterize 
breast cancer tumors, and the text concludes that there is no cure for this 
ailment.4  
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It was almost unheard of for a person to survive breast cancer until the 
introduction of mastectomies.  In the early 1600’s mastectomies became the 
primary treatment of breast cancer in Germany, and within the next few 
centuries this treatment method spread to other western cultures; including the 
United States.  At this time the twenty year odds of surviving breast cancer were 
still 1 in 10.  It wasn’t until William Stewart Halstead from Johns Hopkins 
University developed the radical mastectomy that the twenty year odds of 
surviving breast cancer rose to fifty percent (a radical mastectomy involves 
removing the breast tissue, lymph nodes under the armpits, and the chest 
muscles).  Even with the advent of chemotherapies, super-radical mastectomies, 
and lumpectomies, this was the last great improvement to the 20 year survival 
rate of breast cancer patients in the 20th century.   
In the late 1990’s it was found that the survival rate of people diagnosed 
with cancer had increased from 50% to 68% since the late nineteen seventies.  
This is attributed to the increased ability to diagnose cancer at an early stage, as 
well as improved treatments. Current treatments include surgery, radiation, 
hormone therapy, biological therapy, targeted therapy, and chemotherapy 
(above reference).  It was also around this time that people with early stage 
breast cancer were treated with both surgery and chemotherapy.  This new 
approach came after the repeated confirmation from researchers that 
chemotherapy helped patients stay cancer free for longer periods of time.   
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Chemotherapy 
 A Brief History  
 In 1909 the first modern chemotherapy agent was discovered by physicist 
Paul Ehrlich – the man who coined the term chemotherapy.5  Ehrlich’s objective 
was to find drugs that killed the disease without harming the person, and, in that 
pursuit, he discovered that arsphenamine – a drug which killed the bacteria that 
caused syphilis.  Arsphenamine expanded to the use of sulfonamides and 
penicillin.5  
 It wasn’t until the 1940’s that chemotherapy – nitrogen mustards and folic 
acid – was used to treat cancer.6,7   This line of research started as a result of 
Dr. Stewart Francis Alexander’s findings during the autopsies of people exposed 
to mustard gas bombs during World War II.6  He found that mustard gas reduced 
the reproduction of cells that normally rapidly divided.  Nitrogen mustards were 
then studied in rats, and subsequently patients with non-Hodgkin’s lymphoma.  It 
was discovered that the drug reduced tumor size for a brief period, and therefore 
chemotherapy was shown to be a possible treatment for cancer. 6  After this time 
the word ‘chemotherapy’ became best known as a term for cancer treatment.  
In 1965 combination chemotherapy’s revolutionized cancer treatment.6  
Taking a cue from the treatment of tuberculosis, scientists came up with the idea 
of using several drugs that have different mechanisms of action in one 
treatment.  This would make it more difficult for cancer cells to become resistant 
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to chemotherapies, as well as treat cancer cells in different stages of 
development.  The first combination therapy (POMP regimen) resulted in long 
term remission in children with acute lymphoblastic leukemia.6  Combination 
therapy is used in almost all chemotherapy treatment today. 
Around this time the idea of adjuvant therapy took hold.  It was shown 
that chemotherapy was more effective in smaller tumors; adjuvant therapy is the 
use of chemotherapy after the surgical removal of cancer.8  Several studies 
showed that adjuvant therapy improved the odds of survival in people with 
cancer.  An increase in survival rate was especially noticed in people with late 
stage cancer.8 
 
Classes of Anticancer Drugs 
 There are several different mechanisms and sites of action for 
chemotherapies (Figure I.1).9  The more commonly studied (or traditional) 
classes include: alkylating agents, antimetabolites, plant alkyloids and 
terpenoids, vica alkyloids, podophyllotoxin, taxanes, topoisomerase inhibitors, 
and cytotoxic antibiotics.  These drugs target rapidly dividing cells, including both 
cancerous and healthy tissues (such as hair, gastrointestinal, epithelium, and 
bone marrow).9  Several of these classes will be discussed, after which an in 
depth presentation of the mechanisms most relevant to important metal based 
compounds with anticancer activities will be provided. 
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Figure I.1. Model of in cellulo drug targets (adapted from reference 8). 
 
 
 
7 
Antimetabolites work by inhibiting the ability of the cells to make or 
replicate DNA or RNA.10  There are three types of antimetabolite drugs; those 
that work by impairing folic acid, mimicking purines, or mimicking pyrimidine.10  
Antifolates work by inhibiting the production of tetrahydrofolate, an essential 
compound in the synthesis of purines and pyrimidines.  This leads to a 
decreased synthesis of DNA in these cells.  Antifolates was one of the first 
classes of chemotherapy drugs used, first discovered in 1948 when folic acid 
was used to treat leukemia11.  Purine and pyrimidine analogs work by being 
incorporated into the DNA before replication.  This inhibits the ability of DNA to 
be replicated.11  Antimetabolites are more effective in rapidly dividing cells.  
They affect the cell in the S phase; which is when the cell starts to make new 
DNA for replication (Figure I.2).11 
Mitotic inhibitors encompass a large group of anticancer drugs, for 
example plant alkaloids and terpenoids, vinka alkaloids, as well as taxanes.12  
They work by inhibiting the ability of the cell to undergo mitosis.  An example of 
how some mitotic inhibitors work (eg vinka alkaloids and plant alkaloids) is by 
preventing the formation of microtubules; while taxanes prevent the function of 
microtubules.12  Microtubules are responsible for pulling the cell apart during 
reproduction, and so disrupting the function of microtubules prevents or slows 
cell reproduction.  Mitotic inhibitors work during the M phase of the cell cycle 
(Figure I.2).12 
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Figure I.2. Mitosis cell cycle. 
 
 
Cytotoxic antibiotics work by affecting the DNA.  One study showed that 
mytomycins work by cross linking DNA, causing a leasion that results in cell 
death.13  The major class of cytotoxic antibiotics is anthracyclines; which have 
several known mechanisms of action.14,15  The first is the ability to intercalate 
into DNA and RNA, which inhibits the replication of DNA and RNA.  
Anthracyclines also inhibit the function of topoisomerase, which is responsible 
for interconverting the topological isomers of DNA during replication.14  
Interfering with topoisomerase leads to cell death.  Finally, these compounds 
can also create oxygen radicals with the assistance of iron.14  These oxygen 
radicals can damage both the cell membrane and DNA.  Anthracyclines are one 
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of the most affective chemotherapies, used for the treatment of many types of 
cancer.15  The major problem with these compounds is their cardiac toxicity; 
which is so bad that a lifetime cap is put on the amount of many cytotoxic 
antibiotics a person can receive.14   
While many cytotoxic antibiotics are considered topoisomerase inhibitors, 
there is a class of chemotherapy agents devoted to this mechanism of cell 
death.16  There are two types of topoisomerase enzymes, namely type I and 
type II.17  Both type I and type II can be further broken down, but in this section 
they will be discussed more generically.  Topoisomerase I works by breaking the 
phosphodiester bond on one strand of the DNA in order to decrease the linking 
number, whereas topoisomerase II works by breaking the phosphodiester bond 
on both strands of DNA to decrease supercoiling.  Topoisomerase inhibitors are 
classified based on whether they interfere with topoisomerase I or II.  
Topoisomerase inhibitors work by binding to topoisomerase, therefore 
preventing it from reanealing the break in the phosphodiester bond, and leading 
to cell death (Figure I.3).17,18 
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Figure I.3. Mechanism of topoisomerase inhibitors (adapted from reference 17). 
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 Alkylating agents are electrophilic molecules that work by alkylating 
nucleophilic biomolecules – most importantly DNA bases.  These compounds 
are capable of alkylating many sites on the DNA bases; such as the N1, N3, N6 
and N7 positions of adenine, N1, N2, N3, N7, and O6 positions on guanine, N3, 
N4 and O2 sites in cytosine, and N3, O2, and O4 positions in thymine (where the 
superscripted numbers indicate exocyclic atoms on the nucleobase) (Figure 
I.4).19  These DNA base sites do not all have equal reactivity with alkylating 
agents.  The electrophillicity of the compounds were calculated using the Swain-
Scott equation, found in equation 1, where s is the substrate concentration, n is 
the nucleophilic constant for a nucleophile, k is the pseudo first order rate 
constant, and k0 is the normalized rate constant.  The Swain-Scott equation 
relates the rate constant with the normalized reaction rate (normalized to water 
as the nucleophile) to the nucleophilic constant and substrate constant.  The 
less electrophilic compounds are the ones that react with the less nucleophilic 
oxygen sites – such as O6 on guanine, and the oxygen atoms on the 
phosphodiester backbone of DNA.19  However, the most active site of alkylation 
is the N7 of guanine, followed by the N3 site on adenine (Table I.1).19  
 
 
 
 
sn = log10 (k/k0)      (1)
12 
 
 
 
Table I.1. Relative proportions of alkylation of base pairs (adapted from reference 19).
13 
 
 
 
  
Figure I.4. Schematic figure of prominent alkylation sites on DNA base pairs 
(adapted from reference 19). 
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There has also been evidence that the position on DNA being alkylated is 
not random.  The N7 position on guanine is more nucleophilic in a guanine rich 
sequence.20  Sterics also affect the ability of a site to be alkylated.  In B-DNA 
(which is the most common form), the N7 and O6 of guanine are in the less 
sterically hindered major groove, whereas the N3 of adenine is in the minor 
groove (Figure I.4).20  The steric properties change for the Z-DNA, a left-handed 
structure that is present in small fragments at biological conditions.  In Z-DNA 
the major and minor groove have similar widths, allowing other sites such as C8 
on guanine to become accessible.20 
Alkylating agents are most commonly cell-cycle nonspecific, meaning 
they target cells at all phases of the cell cycle.19,21  This category of drug is used 
to treat a wide variety of cancers, but is more active towards slow growing 
cancers such as solid tumors and leukemia.21  These compounds also target 
cells that rapidly divide, such as cancer cells, but also the cells in the 
gastrointestinal tract, hair, bone marrow, ovaries, and testicles.9,21  This leads to 
many side effects, including infertility and cancer.  Alkylating agents can either 
be monofunctional, or difunctional.  Monofunctional compounds can alkylate only 
one position, whereas difunctional compounds can react with two sites.  
Difunctional compounds can cause DNA cross-linking if the two reactive sites 
are on opposite strands of the DNA.21   
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Cisplatin 
In the history of chemotherapy, the modern era began in 1965.  This was 
an important year in cancer research, as well as medicinal inorganic chemistry, 
as this was the year that Dr. Barnett Rosenberg discovered the antibacterial 
effect of Cis-diamminodichloro platinum (II) (cisplatin).22  Cisplatin was first 
discovered by Peyrone in 1845, and in 1983 Alfred Werner was able to 
structurally characterize the compound, and separate it from its trans isomer.  In 
the 1970’s cisplatin became the first inorganic anticancer drug, becoming the 
most important compound in modern medicinal inorganic chemistry. 
In Dr. Barnett’s study, cisplatin was inadvertently formed by the 
electrolysis of a platinum electrode during an experiment designed to study the 
effect of electromagnetic radiation on cell mitosis.23  The experiment first used 
Escherichia coli (E coli), due to the fact that this bacteria is much easier to deal 
with than human cells. During this experiment Dr. Barnett wanted to use a 
platinum electrode due to the inert nature of the metal.  However, the 
experiments showed that the reproduction of the bacteria was halted.  This 
conclusion was based on the rod-like shape of the bacteria, a characteristic of 
bacteria that cannot replicate.  After repeated experiments (NH3)2Pt(Cl)2 was 
found to be the active compound responsible for the inhibition of binary fusion in 
E coli.22  This species is formed from the platinum released from the electrode 
and the electrolyte, aqueous NH4Cl, that was used.  Further work examined the 
16 
 
 
 
most active platinum (II) analogue, comparing cis-Pt(NH3)2Cl4,  cis-Pt(NH3)2Cl2, 
Pt(NH2CH2CH2NH2)Cl2, and Pt(NH2CH2CH2NH2)Cl4.22  Rosenberg expanded this 
research to different late transition metal compounds to study their effect on the 
binary fusion of E coli (Table I.2).22 
 
Table I.2. Compounds tested for biological activity (adapted from reference 22). 
 
Cisplatin is one of the most affective anticancer compounds to date.  It is 
used to treat several types of cancer, including ovarian, head, neck, bladder, 
cervical, and lung.23,24  Cisplatin is affective for many reasons; it is able to cross 
the cell membrane, or nonpolar regions due to its electronutrality.   Once inside 
the cell, the chlorine ligands are easily replaced by water, making the compound 
active.24,25  The cis position of the leaving groups makes it capable of binding 
interstrand, or intrastrand crosslinking of DNA, as well as DNA protein cross 
linking (Figure I.5).24 
 
 
 
 
1
7
 
 
Figure I.5. Cisplatin binding modes to DNA and biomolecules. 
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Cisplatin is introduced to the body via several methods, depending on the 
form of cancer it is targeting.  It is most typically given intravenously at a rate of 
1mg/minute,24-26 but for liver cancer, melanoma, or glioblastoma it is 
administered intraarterially.26 For ovarian cancer it is an interparitoneal 
injection.26,27  If there is a high chlorine concentration in the blood then the 
compound remains inert until it enters the cell, and so excess saline is 
administered with the drug.26  If there is a low chlorine concentration in the blood 
the chlorine on the cisplatin will dissociate and the compound will become active 
in the blood stream, which interferes with its anticancer activity.25  The first 
organs in which the concentration of cisplatin peaks are the kidneys.  It takes a 
few days for concentrations to peak in the liver, testes, and intestines.23,26  
Once the drug reaches the cell it enters through mechanisms, including 
Copper transporter 1, organic cation transporter, and passive diffusion.24,25,28  
Inside the cell cisplatin loses its chlorine ligands because of the low 
concentration of chlorine inside the cell (3-10 mM Cl- concentration inside the 
cell versus 100 mM concentration outside the cell).  They are replaced by water 
or hydroxyl groups, thereby activating the compound (Figure I.6).25,29  Cisplatin 
is active towards many biomolecules, specifically thiol groups, RNA, 
mitochondrial DNA, and nuclear DNA (Figure I.7).25  Only 1% of cisplatin has 
been shown to reach the nuclear DNA, but this interaction is believed to be the 
cause of cell death. 
  
 19
 
 
Figure I.6. Activation of cisplatin.  
20 
 
 
 
Figure I.7. Interactions of cisplatin in cellulo. 
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The active form of cisplatin is an electrophile, commonly targeting 
phosphate, amino, sulfhydryl, carboxyl, and hydroxyl groups.  Therefore, 
cisplatin is classified as an “alkylating agent” (discussed above).  Similar to other 
alkylating agents, cisplatins main target is the N7 of guanine and the N3 of 
adenine.25,30  It has been found that the most common form of bonding is 
intrastrand cross-linking, with 65% 1,2-d (GpG), 25% 1,2-d (ApG), 5–10% 1,3-d 
(GpNpG).31  These interactions comprise about 90% of the DNA-cisplatin 
lesions, and they induce a 26° bend toward the major groove, and unwind 
supercoiled DNA by 13°.32 Interstrand adducts also exist, and exhibit more 
unusual properties such as the presence of cisplatin binding in the minor groove, 
DNA bending towards the minor groove, and major DNA unwinding.31 
It is thought that the anticancer properties of cisplatin are due to their 
interactions with nuclear DNA, both intra- and interstrand cross-linking.25  Much 
effort has been expended on elucidating the reason for cell death, either 
apoptosis or necrosis.33  It was first posited that the reason for cell death was 
due to the inhibition of DNA synthesis.34-36  Soon after, evidence emerged that 
dispelled this theory when DNA repair deficient cells underwent apoptosis at 
cisplatin concentrations too low to arrest DNA synthesis.  It was also shown that 
22 
 
 
repair proficient cells were able to live at concentrations of cisplatin that should 
inhibit DNA synthesis.35,36  It was clear that repair mechanisms were important to 
the survival or demise of cells treated with cisplatin, but research is still needed 
on the exact mechanisms responsible for apoptosis, necrosis, or survival of the 
cell.  To this end the role of HMG1/2, mismatch repair (MMR), DNA-dependent 
protein kinase (DNA-PK), nucleotide excision repair (NER), and homologous 
recombination (HR) will be discussed. 
The role of HMG1 and HMG2 proteins in conjunction with cisplatin has 
been studied.  HMG1 and HMG2 are small proteins found in eukaryotic cells, 
and while their functions are not fully understood, they are thought to have a role 
in DNA replication, transcription and chromatin assembly.37  HMG1 and HMG2 
contain HMG box domains, which consists of three α-helical regions shown to 
bind to DNA.  In a cancer infected cell treated with cisplatin these proteins have 
an affinity for binding to the kinked structure of DNA, which blocks other repair 
proteins from working.  This leads to a slow repair, or more commonly, cell death 
(Figure I.8).33 
23 
 
 
 
 
 
Figure I.8. DNA repair after being damaged by cisplatin (adapted from reference 
33). 
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MMR has also been shown to interact with DNA bound cisplatin – leading 
to cell death independently of other repair mechanisms.36,38,39  The exact 
mechanism has not yet been proven and there are a few theories as to exactly 
how MMR induces apoptosis.36  What is known is that in cells treated with 
cisplatin, MMR causes intrinsic apoptitic pathways through an increase in 
cytochrome c in the cytoplasm, which promotes the cleavage and activation of 
caspase-9, which subsequently cleaves and activates caspase-3, an effector 
caspase that degrades intracellular proteins causing cell death.36 
In normal cells there are repair mechanisms for double-strand breaks in 
nuclear DNA.  The two mechanisms employed by the cell are recombination 
repair, and nonhomolougous end-joining (NHEJ).40,41  NHEJ is the mechanism 
that has relevance in the toxicity of cells treated with cisplatin; more specifically 
DNA-PK has been implicated in pathways of cisplatin induced cell damage.42  
The protein DNA-PK is brought to a double-strand break by the heterodimer 
Ku70/Ku80, forming a multiprotein.  In normal cells this functions to directly join 
double strand breaks, however, in cancer cells it is also responsible for cell-
interdependent signaling in conjunction with gap junctions to send cytotoxic 
signals to cells surrounding the cisplatin treated cell.42  One study showed that 
cisplatin had a reduced toxicity in cells lacking DNA-PK, Ku80, and gap 
junctions.43,44  This same report also noticed that the confluency of the cells 
affected the toxicity of cisplatin.  When cells are close together there is a higher 
cytotoxicity, than cells that are further apart.  It is thought that cell-
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interdependant mechanisms are responsible for one third of the toxicity of 
cisplatin (the other two thirds is a result of cell-autonomous pathways such as 
those mentioned above).43  This result is dependent on the cell line being used 
as well.  It has been shown in cisplatin sensitive laryngeal tumors that cell-
interdependent mechanisms of cisplatin, specifically relating to gap junctions, 
reduce the motility of cancer cells.43   
DNA repair pathways can also lead to DNA repair and cisplatin 
resistance.  The main repair pathway implicated in cisplatin resistance is 
nucleotide excision repair (NER).45  NER is responsible for repairing DNA that 
has major structural flaws, and there are two pathways by which this can 
happen, namely global genomic NER and transcription coupled NER.46,47  TC-
NER is the pathway that was shown to be active in repairing cisplatin damaged 
DNA.48  The DNA lesion induced by cisplatin stalls RNA polymerase II, signaling 
NER to the repair site.  NER is most efficient at repairing single strand breaks, 
and is used on bulky structural DNA damage – which makes it more effective on 
the 1,3 intrastrand binding mode of cisplatin.36,48   
There are other DNA repair pathways that lead to cisplatin resistant cells, 
although to a lesser extent than the NER pathway.  These include DNA 
polymerase beta, C-fos and C-myc, and p53 (a gene that is intended to 
suppress tumors).  Along with DNA repair pathways, thiol rich biomolecules such 
as glutathione and metallothionein can cause resistance to cisplatin.49   
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Metallothione (MT) is a protein that has a low molecular weight and a high 
content of cysteine residues.  Its exact purpose is not fully understood, but they 
are known to bind heavy metals, and are believed to play a role in both 
protecting cells against heavy metal toxicity and regulating the concentration of 
vital metals in the cell.50-52  MT is shown to bind cisplatin in vivo through one of 
its SH moieties.53  Upon binding, the MT-cisplatin adduct is exported from the 
cell, and can be seen in increased concentrations in the blood stream.54  It has 
also been shown that as the MT concentration inside a cell increased, the 
effectiveness of cisplatin decreased.55  
Aside from DNA repair mechanisms; there are other factors that induce 
acquired resistance to cisplatin in cells.  Low concentrations of intracellular 
cisplatin cause have been postulated to cause resistance to cisplatin.53  Low 
intracellular concentrations can be caused by down-regulation of the receptors 
that allow cisplatin to enter the cell.53  When cisplatin does enter the cell, it can 
interact with biomolecules other than intended targets such as glutathione and 
metallothionein.  These interactions can lead to the removal of cisplatin, and the 
resistance of cancer cells to this drug.53 The role of glutathione in cisplatin 
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resistance has been debated for the last several decades; but recent evidence 
has led to strong indication that glutathione does indeed induce cisplatin 
resistance in cancer cells.56  This study has looked at cisplatin resistant cells 
after inhibiting the reactivity of glutathione.  The results showed that the cells 
which were resistant to the toxic effects of cisplatin before the inhibition of 
glutathione were now susceptible to the drug.49 
In conjunction with cell resistance to cisplatin, the severe side effects 
attributed to the toxicity of cisplatin to healthy cells is a limitation of cisplatin.  
The dose limiting side effects of cisplatin include nefrotoxicity (damage to the 
kidneys), ototoxicity (damage to the ear – mainly the cochlea and auditory 
nerve), and nausea and vomiting.23  Because of the severe side effects, and 
inherent and acquired resistance to cisplatin, there have been several 
generations of platinum and other inorganic analogues developed in an effort to 
improve upon the anticancer properties of cisplatin by minimizing the side 
effects, reducing the resistivity, and allowing for a more convenient method of 
delivery (Figure I.9).23   
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Figure I.9. New generations of platinum based drugs (adapted from reference 
23). 
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New Generations of Cisplatin 
 New generations of platinum based anticancer drugs have been 
developed in an effort to improve upon cisplatin.57,58  The first cisplatin analogue 
to be approved for use in the United States was carboplatin.23  Carboplatin was 
first approved as a palliative treatment for ovarian cancer.23  Carboplatin was 
developed in an attempt to reduce the toxicity of cisplatin, while maintaining its 
mechanism of action by making a more stable leaving group.  The toxicity of 
carboplatin is less than that of cisplatin, with the main dose limiting toxicity being 
myelosuppression (bone marrow suppression) and thrombocytopenia (decrease 
in blood platelets); the nephrotoxicity that is the dose limiting side effect in 
cisplatin is greatly reduced.  The nausea and vomiting associated with cisplatin 
is also reduced in carboplatin.  The range of effectiveness for carboplatin is 
mainly ovarian cancer, but it is an adjunct therapy for other cancer types such as 
non-small-cell lung cancer (Figure I.10).23   
New cisplatin analogues have a broader spectrum of antitumor activity 
with reduced resistance.23 There are several platinum based drugs that have 
been approved by the FDA, or are currently under investigation, including: 
oxaliplatin, satraplatin, and picoplatin.  Oxaliplatin was the third platinum based 
drug approved by the FDA, and has been shown to be effective against some 
cell lines that are resistant to cisplatin and carboplatin.  This is thought to be 
caused by the ability of oxaliplatin to bind DNA via modes not observed with 
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cisplatin, or carboplatin.  As a result of the different antitumor activities, 
oxaliplatin is active against some cisplatin resistant cell lines.  satraplatin is 
another example of a cisplatin derivative that has shown to be active against 
cisplatin resistant cells.23  In addition to overcoming resistance mechanisms, 
satraplatin has also improved methods of delivery.23 As previously mentioned, 
cisplatin is given intra-venously, intra-arterially, or as an inter-paritoneal 
injection.  New analogues, such as satraplatin, can be taken orally and still show 
similar levels of antitumor activity (Figure I.11).23  These new derivatives have 
improved upon cisplatin disadvantages, and one of the most studied bioactivities 
of cisplatin which leads to acquired resistance is the interaction with glutathione.  
Picoplatin, one of the most recent analogues, has reduced interaction with 
glutathione, and other biomolecules that contain thiol groups.  This reduced 
interaction is believed to be due to the bulky groups that protect the platinum 
core from interaction with the thiol groups of glutathione, therefore reducing the 
amount of drug that is rendered inactive (Figure I.12).23 
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Figure I.10. Cisplatin drugs that are in, or are close to entering into, drug trials. 
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While these new platinum drugs have greatly improved the toxic side 
effects of cisplatin, efforts have been made to increase the specificity of platinum 
drugs to cancer cells.23,57  To this end, there are drugs currently being tested by 
the FDA which use liposomes, or water soluble co-polymers, to target tumor 
cells.    Aroplatin is the lead platinum based liposomal drug, and is being tested 
in colorectal cancer.  The toxicity of aroplatin towards cancer cells is not as high 
as cisplatin, and further work is being carried out in an effort to improve 
anticancer properties.  AP5346 is another platinum based drug which employs a 
water soluble polymer.  This drug was developed to take advantage of the 
enhanced ability of tumors to take in and retain of macromolecules.  The 
activation of this drug in more acidic environments could lead to enhanced ability 
to treat solid tumors which have a low pH.23  Platinum based drugs have shown 
promising anticancer activity, particularly the platinum compounds with 
structures that differ from cisplatin, such as those with trans geometries or 
octahedral geometries, and also polynuclear platinum compounds, as well as 
compounds with ligands that are bulky or water soluble.57  The success of these 
drugs has prompted research into the exploration of other metals that have 
promising anticancer properties as well.   
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Figure I.11. Cisplatin and derrivatives that have been approved for use as a 
drug (not neccessarily in the United States). 
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Figure I.12. Novel platinum based compounds 
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 Inorganic Drugs 
 There are many metal based compounds that exhibit toxicity towards 
cancer cells.  Metal centers such as vanadium, titanium, chromium, copper, iron, 
molybdenum, ruthenium, rhodium, osmium, rhenium, iridium, and gallium have 
been investigated.58,59  The success of cisplatin opened the door for medicinal 
inorganic chemistry to develop, and the metal based compounds being explored 
have a range of activities from DNA intercalation to “trojan horse” clusters that 
house toxic compounds.  Among the metal compounds that have shown 
biological activity are metallocenes, which are thought to be redox active 
towards biomolecules.60  The redox potentials inside the cell are not known, and 
the mechanisms of these compounds are still under investigation.  The most 
bioactive metallocene compounds to date are bent, with the two cis halide 
ligands.  It is interesting to note that a derivative of ferrocene, ferroquine, is one 
of the metal complexes in the late stages of FDA testing (phase III); it has been 
shown to be active against malaria.  Some of these ferrocene analogues have 
also been shown to cross the blood-brain barrier; something that most drugs 
cannot do.60   
 Ruthenium compounds have also shown promising activity that is 
dissimilar to cisplatin.  Two ruthenium compounds, KP1019 and RuNAMI-A 
(Figure 1.13), were the first ruthenium compounds to enter clinical trials.58,61  
The compound KP1019 has activity against tumors, and RuNAMI-A is active 
against metastasized cancer cells.  Another class of ruthenium compounds, 
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known as “RAPTA” compounds, have been probed for anticancer properties, 
and show similar activity to the RuNAMI-A.  RAPTA compounds have a piano 
stool geometry, which allows for one side of the ruthenium compound to be 
hydrophobic (with respect to the aromatic group), with the other side containing 
ligands that are hydrophilic. 
 
 
Figure I.13.  Other metal based drugs that have shown anticancer properties.
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Dirhodium Compounds 
Dirhodium tetraacetate was first synthesized in 1963, and in 1970 the 
crystal structure was obtained. 62  This compound has a paddlewheel structure 
(Figure I.14), with the four acetate ligands binding in a bridging mode to the 
dirhodium core, with a Rh-Rh single bond of 2.40 ± 5 Å.62  There are two 
different types of positions available for binding – the equatorial and the axial 
positions.  The equatorial ligands bind more tightly to the dirhodium core, and 
are therefore more difficult to substitute.  The axial positions are more weakly 
bound to the dirhodium core, and are usually occupied by the solvent in which 
the compound was las dissolved (commonly methanol, water, or acetonitrile).62  
An interesting property of this compound is that its color depends on its axial 
ligands.  When water or other oxygen donating ligands are present, the molecule 
is a green-blue color.  However, when nitrogen ligands occupy the axial 
positions the color is violet; sulfur causes a more burgandy color, and 
phosphorous bound axial ligands lead to an orange color.  The spectroscopic 
changes introduced by the axial donor are caused by the fact that the LUMO is 
the σ* orbital, and thus the nucleophilic properties of the axial ligands effect the 
energy of this orbital.  The Rh-Rh bond distance is not very dependent on the 
axial ligand (Figure I.14).62   
The anticancer properties of dirhodium tetraacetate and some derivatives 
(Rh2(O2C2R)4, where R = CH3, C2H5, and C3H7)  were first reported in the late 
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1970’s.  This series was found to be active against Ehrlich ascites leukemia 
1210, and sarcoma 180 and P388 cell lines.63  While this series did not 
represent the properties of typical therapeutic agents they were shown to have 
good anticancer properties, and reduced side effects as compared to cisplatin.  
Further investigation into dirhodium compounds focused on paddlewheel 
compounds with varying electron donating properties.64,65  It was found that 
dirhodium paddlewheel compounds with electron withdrawing groups, such as 
dirhodium tetrakis trifluoroacetate, exibit a higher toxicity against cancer cells.9  
The trifluoroacetic acid derivative was found to show activity against Ehrlich 
ascites tumors, and increased the lifetime of rats bearing this cancer.  A similar 
derivative, trifluoroacetamide, (which binds rhodium through oxygen and 
nitrogen, as opposed to thrifluoroacetate which binds through only oxygen 
donors) was shown to have similar activity to cisplatin.  This compound 
increased the lifetime of 90% of the rats bearing Ehrlich ascites tumors.65,66 
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Figure I.14. Structure of dirhodium tetraacetate. 
 
 
Other paddlewheel compounds, such as formamidinates which include 
the DTolF derivative (where DTolF is ((CH3)C6H4)2N2CH) have been tested for 
anticancer activity as well (Figure I.15).  The tetraformamidinate derivatives do 
not show high toxicity in cancer cells, however, mixed paddlewheel compounds 
of formamidinate have toxicity towards cancer cells.  An example of this is 
Rh2(DTolF)2(O2CCF3)2, which show similar activity towards Yoshida ascites and 
T8 sarcomas as cisplatin.  The promising anticancer properties of dirhodium 
paddlewheels lead to the need for further investigation into the mechanisms of 
biological activity.67 
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           Figure I.15. Dirhodium paddlewheel derrivatives tested for anticancer 
properties. 
 
 
Interactions Between Dirhodium Compounds and DNA 
 One of the first objectives towards determining the cause of cytotoxicity 
was to determine if dirhodium tetraacetate could bind to DNA, as was observed 
with cisplatin.  It was shown early on by Bear and coworkers that the dirhodium 
compound was capable of binding 1-methyladenosine.68  The aqueous 
dirhodium solution changed from blue/green to a pink color, which indicated that 
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the 1-methyladenosine was axially bound through a nitrogen atom.  Similar 
reactions with guanine did not yield any adducts with dirhodium tetraacetate.68  
When a crystal structure of the axially bound 1-adenosine was obtained, it was 
shown that the oxygen atom from the acetate group was able to hydrogen bond 
with the amine group.  This observation led to the hypothesis that guanine could 
not bind to dirhodium carboxylates because of the repulsive interaction between 
the O6 on guanine, and the oxygen of the acetate ligand.  These interactions 
showed that dirhodium tetraacetate could interact with DNA, but it did not seem 
possible that the weak interaction between dirhodium and its axial ligands could 
cause the cytotoxicity exhibited by these compounds (Figure I.16).69 
 Later experiments revealed that dirhodium tetraacetate could bind 9-
ethylguanine via a bridging mode. 69  Two of the acetate groups were replaced 
by the 9-ethylguanine, which is bound in the equatorial positions through O6/N7 
positions on the purine.  This results in both a head-to-head, and head-to-tail 
arrangement of the dirhodium 9-ethylguanine compound (Figure I.17). 69  Similar 
reactivity was found with the trifluoroacetic acid dirhodium derivative as well.  
Results of further studies indicated that 9-ethyladenine binds to the equatorial 
positions when reacted with the dirhodium compound Rh2(DTolF)2(O2CCF3)2.70  
The adenine replaces the trifluoroacetate groups, binding via the O6/N6 
positions.  The 1H NMR studies of this product revealed that the adenine was 
bound in the rare imido form, indicating that if this interaction occurs in dsDNA it 
could interfere with the hydrogen bonding of the base pairs (Figure I.17).70 
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 Following the successful studies of cisplatin the binding mode of 
[Rh2(DTolF)2(CH3CN)6]2+ with the dinucleotides d(GpG) and d(pGpG) was 
studied by 2D NMR experiments.  After determining the binding motif of these 
compounds, molecular modeling was used to determine the probable structure 
of Rh2(CH3CO2)2(d(pGpG)).  The calculated conformation of 
Rh2(CH3CO2)2(d(pGpG)) was overlaid with the crystal structure of 
Pt(NH3)(d(pGpG)), revealing that the two binding modes are extremely similar.  
The interaction of [Rh2(DTolF)2(CH3CN)6][BF4]2 with the mixed adducts d(ApG) 
and d(GpA) were also studied by 2D NMR spectroscopy.  This experiment 
provided evidence that dirhodium compounds are capable of binding mixed 
purine fragments.  While it took longer for the dirhodium d(ApG) adduct to form, 
both of the dinucleoties reacted with the compound.  Once again the adenine 
was found to be stabilized in its imido form.71 
 
 
 
Figure I.16. a) Dirhodium tetraacetate axially binding to adenosine. b) Dirhodium 
tetraacetate with axial guanine. 
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Figure I.17. Dirhodium equatorial binding to A) HT guanine B) HH guanine C) 
HT (adapted from reference 70). 
A) B) 
C) 
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The next step was to probe the ability of dirhodium compounds to bind to 
double stranded DNA.  Matrix-assisted laser desorption ionization (MALDI) and 
nanoelectrospray (nanoESI) coupled to time-of flight mass spectrometry (TOF-
MS) were used to determine the products of the interaction between 
Rh2(O2CCH3)4 and DNA fragments.72,73   The duplex DNA strands were 
designed to have AA, GG, GA, and AG sequences in order to obtain insight into 
the favored purine arrangement for binding.  It was shown that dirhodium 
preferentially binds to AA and GG sequences.71,74  A subsequent detailed study 
was conducted to probe the interactions of Rh2(O2CCH3)4 with the DNA duplex, 
d(CTCTC*A*ACTTCC).(GGAATTGAGAG).75  The compound was first incubated 
with d(CTCTCAACTTCC), and then annealed to the other strand.  The 
surprising results of this experiment showed that the compound Rh2(μ-
O2CCH3)2(η1-O2CCH3)]+ formed an intrastrand adduct by binding to the C5 and 
A6 bases on the 5’ strand.  The 2D NMR data indicated that the dirhodium 
compound was bound to the exocyclic N4 of the cytosine, and the N7 of the 
adenosine; greatly destabilized the duplex DNA.75   
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Interaction of Dirhodium Compounds with Other Biomolecules 
 The process and logic used to develop an intimate understanding of the 
anticancer activity of cisplatin has helped guide the investigation of dirhodium 
compounds.  To this end the biologically relevant interactions of several 
dirhodium comounds (Figure I.18) were investigated.  This includes dirhodium 
compound activity towards transcription inhibition,76 their interaction with 
glutathione,77 the mechanism of cell death,78 and the ability to reach nuclear 
DNA.79  The interaction with glutathione was tested in solution with series 3 (as 
indicated in Figure I.18).  EPR spectroscopy indicated that glutathione was able 
to reduce the dirhodium compounds, and that the reduction is reversible.  After 
these studies a series of compounds (series 4 in Figure I.18) was tested in 
media that contained glutathione.  The activity of the series of compounds 
remained very close to the control tests, which showed that the reactive radical 
species shown to be formed in previous tests were not responsible for cell 
death.  This was also a promising preliminary result as glutathione is known to 
cause resistance in cancer cells treated with cisplatin.   
Transcription inhibition experiments were carried out for series 1 and 2 
(Figure I.18).  For the first series the transcription inhibition is caused by the 
compounds binding to T7-RNA polymerase (T7-RNAP).  The level of inhibition 
for these compounds is higher than that of cisplatin.  The activity of the series 
that showed transcription inhibition is related to the redox activity of the 
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compounds.  The redox chemistry can be controlled by changing the R groups 
at the distal end of the diimine ligand.  Because the activity is related to the 
redox potential of the compounds, it was concluded that the dirhodium series 
interacts with exposed thiol groups in T7-RNAP.76,77   
 The mechanism of cell death was tested for compounds in series 5 
(Figure I.18).  All of the compounds in the series were shown to induce 
apoptosis, except for the dirhodium compound possessing two dppn 
(benzo[i]dipyrido[3,2-a:2',3'-c]phenazine) ligands.  The morphology of the dead 
cells indicated that the mechanism for cell death wasnecrosis.79  In addition to 
the mechanism of cell death, ongoing efforts are aimed at determining the 
localization of dirhodium compounds in vitro.79  Studies indicated that 
compounds from series 5 were able to reach nuclear DNA, whereas series 1 
was not.  There is far too much work on these series to be thoroughly covered in 
this introduction, but suffice it to say the intricate nature of biological processes 
demands careful and systematic analysis of drugs to fully understand their in 
vitro, and in vivo mechanisms.78  
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Objectives 
Dirhodium compounds have been studied for decades, and have shown 
promising results as anticancer agents.  The ability to control the properties of 
these compounds based on the ligands allows for the rational development of 
dirhodium compounds with specific biological activities.  The Dunbar group has 
been investigating dirhodium tetraacetate and its derivatives in an effort to 
understand and improve their anticancer properties.  In addition to improved 
toxicity towards cancerous cells, it is important to decrease the toxicity to healthy 
cells in an effort to reduce the severe side effects seen in cisplatin. 
My research has focused on characterizing and studying the cytotoxicity 
and photocytotoxicity of dirhodium series.  Chapter II describes the series 
[Rh2(O2CCH3)(N-N)2]2+, where N-N are the diimine ligands: 1,10-phenanthroline 
(phen), dipyrido[3,2-f:2',3'-h]quinoxaline (dpq), dipyrido[3,2a:2´,3´c]phenazine 
(dppz), and benzo[i]dipyrido[3,2-a:2',3'-c]phenazine (dppn).  Because this series 
is composed of compounds that have been investigated before in various 
experiments, it was my goal to start assembling the pieces of the puzzle, and to 
fill in any missing information.  The ultimate goal is to relate the structures to the 
activities of the dirhodium diimine compounds. 
A second goal was to alter the electronic transitions of the dirhodium 
diimine series upon irradiation of light.  Several of the compounds studied in the 
Dunbar group have been tested as possible photodynamic therapy (PDT) 
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agents.80-82  PDT will be further discussed in the following chapters, but one 
important property of a useful PDT agent is to be able to be activated by low 
energy irradiation (the PDT window is 600 to 850 nm).83  To this end, efforts in 
the Dunbar group are focusing on studying the effects that the bridging ligand 
has on the energy of light required to activate the compound.  Chapter III 
describes the synthesis and characterization of a new series of orthometalated 
dirhodium compounds using the same diimine ligands.  The cytotoxicity and 
photocytotoxicity properties were measured and compared to the analogous 
dirhodium carboxylate series. 
The promising anticancer properties of several metal based compounds 
in conjunction with the benefits of metal-metal bonded systems has steered my 
research towards studying the biological activities of diiridium compounds.  
Diiridium (II, II) compounds are not well studied, presumably because they are 
much less easy to work with than their dirhodium (II,II) analogues.  Chapter IV 
details a new synthesis of [Ir2(DTolF)2(CH3CN)6]2+ and studies of its cytotoxicity 
and photocytotoxicity. 
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Figure I.18. Series of dirhodium partial paddlewheel compounds that have been explored for biological activity. 
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CHAPTER II 
CARBOXYLATE BRIDGED DIRHODIUM PARTIAL PADDLEWHEELS: 
SYNTHESIS AND CYTOTOXICITY STUDIES 
 
Introduction 
 Dirhodium compounds have been known to be cytotoxic towards cancer 
cells since the 1970’s.63  They present the possibility of tuning the anticancer 
activity based on the structure and properties of the ligands.84  Knowing how the 
features of ligands affect the biological activity of these compounds is essential 
to designing drugs that have the desired properties.  The Dunbar group has 
focused on the synthesis and biological activity of dirhodium partial paddlewheel 
compounds with extended π-conjugated bidentate diimine ligands.76,78,79,85  
Pruchnik was the first to investigate the anticancer properties of this type of 
compound in 1996, when [Rh2(O2CCH3)2(phen)2]2+ was shown to have cytostatic 
activity against the human oral carcinoma KB cell line.86,87  Soon after the 
anticancer effect of the dirhodium phenantroline compound was found, Pruchnik 
reported the antibacterial effect of this compound, and its interactions with 
adenosine triphosphate.88  In parallel studies, the Dunbar group reported the 
ability of this compound to inhibit RNA transcription.77,89 
 Many dirhodium compounds have been found to be cytotoxic – in some 
cases more so than cisplatin.  The high cytotoxicity of cisplatin towards cancer 
cells has made it one of the most effective anticancer drugs, but the toxicity of 
Series 1 
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cisplatin extends to healthy cells as well.  This leads to many negative side 
effects (such as the dose limiting nephrotoxicity).23  Therefore it is necessary to 
find a way to limit the toxicity of these compounds towards healthy cells.  There 
have been many methods of drug delivery reported in the literature which 
endeavor to limit the toxicity of drugs to healthy cells.  Many of these 
approaches work by specifically targeting the delivery of toxic compounds to 
cancer cells, including the use of aptomers, cell penetrating peptides, and 
liposomes.9  Photodynamic therapy (PDT) is another method aimed at reducing 
the toxicity of the drug to specific regions, that is to say tumors.90     
 Photodynamic therapy agents are non-toxic in the dark, and become 
cytotoxic upon irradiation with light.  In a clinical use, the inert PDT agent is 
administered in the dark and the region of the tumor is irradiated in order to 
activate the drug.  Therefore, PDT agents need to have some specific 
properties; first a high ratio between the cytotoxicity in the dark, and the 
cytoxicity upon irradiation (referred to as photocytotoxicity), and finally the 
wavelength of light needed to activate the compound should be in the near 
infrared range of 600-850 nm.  This second property is required because red 
light is known to be able to more deeply penetrate tissue.90   
 The current PDT drug approved for use as an anticancer agent by the 
FDA is photofrin®, a drug that consists of oligomers of porphyrin units.  The 
photocytotoxicity of this drug (LC50 is 3.8 ± 1 μM) is 5 times greater than the 
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cytotoxicity in the dark (LC50 is 21 ± 0.2 μM).  The wavelength needed to 
activate the compound is 630 nm, which is inside the PDT window.  Photofrin®, 
and most other PDT agents, works by sensitizing singlet oxygen, which is known 
to damage DNA and other biomolecules.  The quantum yield of sensitized 
singlet oxygen for photofrin® is 0.17 (found in methanol).  The disadvantage of 
using singlet oxygen as the mechanism of photocytotoxicity is that many of the 
most malignant and drug resistant tumors are hypoxic.  The prolonged 
cutaneous sensitivity is another negative aspect of current PDT drugs.  For 
these reasons new classes of PDT agents with improved properties are being 
sought. 
 Dirhodium compounds were first investigated for their photoactivity in 
biological systems because of the ability of these compounds to exhibit long-
lived excited states with lifetimes of 3.5 - 5 μs.  Also, the neutral or positive 
charges of these compounds prevent electrostatic repulsion with DNA.91  It was 
found that both Rh2(O2CCH3)4 and  [Rh2(O2CCH3)2(phen)2]2+ could photocleave 
DNA in the presence of an electron acceptor.81  The potential of dirhodium 
diimine compounds to act as PDT agents was further investigated for dirhodium 
dppz compound, where dppz is dipyrido [3,2a:2´,3´c]phenazine.  The ligand 
dppz was chosen because of the dearth of metal-dppz compounds that are 
photoactive.80,92  This includes the series [Ru(L)2(dppz)]2+, where L is 2,2’-
bipyridine (bpy), or 1,10-phenantroline (phen), which exhibit luminescence in the 
presence of DNA, and the bpy derivative was shown to be able to photocleave 
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DNA.93  The dirhodium dppz compounds explored are the di-substituted and 
mono-substituted compounds, [Rh2(O2CCH3)2(dppz)2]2+ and 
[Rh2(O2CCH3)2(dppz)(η1-O2CCH3)(CH3OH)]+ respectively, and their photo-
activity with DNA, and LC50 values in the dark and light were 
investigated.80,81,85,94  Both compounds were found to photocleave DNA upon 
irradiation with visible light, λirr ≥ 375 nm.  The analysis of the cytotoxicity of 
these compounds in a human skin cell culture revealed LC50 values of 135 ± 8 
μM and 27 ± 2 μM, and the photocytotoxicity resulted in LC50 values of  39 ± 1 
μM and 21 ± 3 μM (for [Rh2(O2CCH3)2(dppz)2]2+ and [Rh2(O2CCH3)2(dppz)(η1-
O2CCH3)(CH3OH)]+ respectively).  It can be seen that the LC50 values for the 
dirhodium compounds with one coordinated dppz ligand did not change, which is 
attributed to the ability of these compounds to intercalate into DNA.  The LC50 
values of the homoleptic dirhodium dppz compound showed a 3.5 fold decrease 
in the LC50 values (135 ± 8 μM in the dark to 39 ± 1 μM upon irradiation).94   
 The photoactivity of a related series, namely the cations 
[Rh2(O2CCH3)2(dppz)(L)]2+, was subsequently studied (where L is bpy, phen, 
dpq (dipyrido[3,2-f:2',3'-h]quinoxaline), dppz, or dppn (benzo[i]dipyrido[3,2-
a:2',3'-c]phenazine).78,95  Because the toxicity of PDT agents is often caused 
from the creation of singlet oxygen upon irradiation, the quantum yield of singlet 
oxygen was determined for each compound in the series.  The quantum yield of 
singlet oxygen ranged from 0.9 for the phen derivative to 0.4 to the homoleptic 
dppn derrivative.95  Other studies aimed at finding the biological activity of these 
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compounds upon irradiation include the ability to photocleave DNA, and the 
cytotoxicity and photocytotoxicity.  The most interesting results were observed 
for the homoleptic dppz and dppn compounds.  For both compounds the 
photocleavage of DNA was not as high as other compounds in this series, and 
the cytotoxicites were low (355 ± 18 and 384 ± 24 for the dppz and dppn 
derivatives respectively).  The photocytotoxicities of these compounds revealed 
LC50 values of 17 ± 3 μM and 16 ± 4 μM respectively.  This is a 21 and 24 fold 
increase in cytotoxicities upon irradiation.80 
 While much work has been carried out on the compounds 
[Rh2(O2CCH3)2(L)2]2+, where L is phen, dpq, dppz, and dppn, but they have 
never been studied systematically as a series.  This chapter reports the 
synthesis, structural characteristics, and biological relevance of these 
compounds.  The data on these compounds are compiled to asses how the 
structural characteristics relate to the biological properties of these compounds, 
and evaluated according to their potential to be used in photodynamic therapy. 
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Experimental Section 
Materials 
The reagents 1,10-phenanthroline, 1,2 phenylene diamine, and 2,3 
diaminonapthalene were purchased from Acros, and used as received.  The 
starting material Rh2(μ-O2C2H3)4 was purchased from Pressure Chemicals and 
used as received.  The HeLa cell line was obtained from the American Type 
Culture Collection.   
The starting material 1,10 phenanthroline 5,6 dione was used to 
synthesize the ligands dipyrido[3,2-f:2',3'-h]quinoxaline (dpq),96 
dipyrido[3,2a:2´,3´c]phenazine (dppz),97 benzo[i]dipyrido[3,2-a:2',3'-c]phenazine 
(dppn);98 all according to published procedures.  The dirhodium compounds 
[Rh2(CH3CO2)2(phen)2][CH3CO2]2 (1), [Rh2(CH3CO2)2(dppz)2][CH3CO2]2 (3), and 
[Rh2(CH3CO2)2(dppn)2][CH3CO2]2 (4) were synthesized according to published 
procedures.78,81,89,94 
 
Synthesis of [Rh2(CH3CO2)2(dpq)2][CH3CO2]2 (2) 
Solid dpq (0.380 g, 2.00 mM) was added to a solution of (0.100 g, 10.0 
mM) dirhodium tetraacetate in 20 mL of distilled acetonitrile.  The mixture was 
heated to reflux for 24 hours under a dinitrogen atmosphere, during which time it 
turned from purple/brown color to a brown/red color.  At this time the solution 
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was cooled to room temperature, and the resulting precipitate was collected by 
vacuum filtration, and washed with cold acetonitrile.  The product was obtained 
in an 82% yield. 1H NMR (300 MHz) CDCl3/CD3OD (1:1, v:v) ɗ/ppm (mult./ 
integral/ assignment): 1.71 (s, 6H, CH3CO2), 2.65 (s, 6H, CH3CO2), 7.62 (m, 
4H), 8.50 (d, 4H), 8.81 (m, 4H), 8.90 (d, 4H).  UV-vis in H2O λ/nm (ε/M-1cm-1): 
362 (10500), 483 (3000), 580 (1300). 
 
Instrumentation 
The 1H NMR spectra of the new complexes were recorded on a Varian 
spectrometer at 300 MHz and referenced to the residual proton impurities in the 
deuterated solvents. Absorption measurements of solutions were performed on 
a Shimadzu UV 1601PC spectrophotometer, and 96 well plate measurements 
were performed on a GloMax® Multi Detection System.  
 
Methods 
Cell Culture 
 The HeLa cell line was cultured in Dulbecco’s modified Eagle medium 
with 4.5 mg/mL glucose, and 4 mM L-glutamine (Invitrogen), and was modified 
to include 10% fetal bovine serum (Atlanta Biologicals), 50 μg/mL gentamicin.  
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Cell cultures were incubated in a humidified atmosphere at 37 °C which 
contained 5% CO2. 
 
In Vitro Cytotoxicity and Photocytotoxicity  
 The LC50 concentrations in HeLa cells of the compounds under 
investigation were determined using the 3-(4,5-dimethylthiazol-2-yl)-d,5-
diphenyltetrazolium bromide (MTT) assay (invitrogen).99  A 100% confluent 
monolayer of cells in sterile 96 well plates were used for this experiment.  The 
cells were plated at a concentration of 24-36 cell/μL using 100 μL per well, they 
were and incubated for 48 hours.  Once confluent, the media was replaced with 
100 μL of Lebovitz-15 (L15) media (containing no phenol red).  The compounds 
were incubated for 2 hours, then the wells were washed with 1% dibasic 
phosphate buffer and the compound solution was replaced with L15 media.  The 
plates that were used to determine photocytotoxicity were then irradiated for 20 
minutes with λirr = 350 nm.  The plates used for cytotoxicity and photocytotoxicity 
were incubated for 24 hours from the time the compounds were added.  Then 10 
μL of fresh MTT solution was added to each well.  After 4 hours of incubation, 
100 μL of fresh SDS solution in 0.01M HCl was added to each well.  The plates 
were incubated for another 4 hours, then the plates were read at 570 nm using a 
GloMax® Multi Detection System.  Each concentration of compound had six 
wells per plate, and three plates were run per compound.  
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Results and Discussion 
Synthesis and Characterization of the Series [Rh2(O2CCH3)2(N-N)2][O2CCH3]2  
 The synthesis and characterization of the compounds in this series, 
[Rh2(CH3CO2)2(phen)2][CH3CO2]2 (1), [Rh2(CH3CO2)2(dppz)2][CH3CO2]2 (3), and 
[Rh2(CH3CO2)2(dppn)2][CH3CO2]2 (4), have all been reported with the exception 
of [Rh2(CH3CO2)2(dpq)2][CH3CO2]2 (2).  This series results from the substitution 
of two bridging acetate groups from the starting matierial Rh2(O2CCH3)4 for 
bidentate diimine ligands under refluxing conditions in the presence of the 
diimine ligand (Figure II.1).   
 
 
Figure II.1. Synthesis of the compounds 1-4. 
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 The series was characterized by a combination of methods, including X-
Ray crystallography and spectroscopic methods, namely 1H NMR and electronic 
absorbtion spectroscopy.  For the compounds characterized by X-Ray 
crystallography, the Rh-Rh bond distances are 2.525(7) Å, and 2.551(9) Å for 
[Rh2(CH3CO2)2(phen)2][BF4]2 and [Rh2(CH3CO2)2(dppz)2][BF4]2 respectively.94  
The crystal structure of the dirhodium dppz derivative reveals a splaying of the 
dppz ligands and an internal twist angle of 13°, which helps to reduce the 
repulsive forces the dppz ligands would otherwise experience.94  The distance at 
the distal end of the dppz ligands in the dirhodium structure was found to be 
3.494(7) Å.  The 1H NMR of the compounds in the series all show coordinated 
and free acetate ligands at 2.6 and 1.7 ppm respectively.94  For compound 3, the 
protons on the aromatic rings of the diimine ligands (dpq) are between 7.62 and 
8.90 ppm.  The electronic absorbance of the compounds in the series have 
similar properties, namely a transition between 325 - 377 nm – believed to be 
ligand based π to π* transitions, and a transition in the range 373 - 483 nm – 
which are assigned to charge transfer transitions involving the diimine ligand.   
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Cytotoxicity and Photocytotoxicity 
 The cytotoxicity and photocytotoxicity properties of the dirhodium 
bisacetate diimine series (compounds 1-4) in HeLa cells were determined by the 
MTT (3-(4,5-dimethylthiazol-2-yl)-d,5-diphenyltetrazolium bromide) assay.  The 
MTT assay is a colorimetric assay that is used to quantify the number of living 
cells.  In the presence of living cells the yellow tetrazole compound is reduced to 
the purple formazan form by the mitochondrial reductase.  The concentration of 
purple formazan is measured at 570 nm, and can be plotted against the 
concentration of compound added to find the equation for the linear trend line.  
From these data the concentration of compound needed to kill half of the cells 
(lethal concentration of 50%, LC50) can be extrapolated.99   
The range of concentrations used to measure the cytotoxicity of 
compounds 1-4 were chosen based on previous data for similar compounds.  
The range of concentrations measured for this series was 50 μM to 800 μM.  For 
all off the MTT assays, both light and dark, the amount of ambient light was 
limited as much as possible, and experiments used to determine the 
photocytotoxicity exposed the cells to light for 20 minutes.  The results are 
summarized in Table II.1. 
 The values reported in Table II.1 represent the μM concentration of 
compounds 1-4 needed to kill 50% of HeLa cells.  In the dark, compounds 2, 3, 
and 4 have similar in vitro cytotoxicities ranging from 126 μM to 152 μM, while 
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compound 1 is less cytotoxic, with and LC50 of 446 ± 16 μM.  The 
photocytotoxicity values show more deviation between compounds with 
compound 4 being the most photocytotoxic, and compound 1 is the least 
photocytotoxic.  Compounds 2 and 3 have similar photocytotoxicities.  When 
comparing the cytotoxicity and photocytotoxicity of the series the major 
difference is that the photocytotoxicity of compound 4 is no longer similar to 
compounds 2 and 3, as was seen in the cytotoxicity.   
To further explore this trend the ratio of cytotoxicity to photocytotoxicity of 
each compound was found.  For compound 1 the ratio between cytotoxicity and 
photocytotoxicity is 1, indicating that irradiation has no effect on the toxicity of 
the compound towards HeLa Cells.  Compounds 2 and 3 have similar ratios of 
toxicity in the dark and light, 1.5 and 1.2 respectively.  It is possible that 
irradiation affects the LC50 concentrations of these compounds; yet, if this is true 
it is only slightly.  Compound 4 differs from the others in that its ratio of toxicity in 
dark and light is 2, meaning that the photocytotoxicity of compound 4 is twice 
that of its cytotoxicity.  The change in toxicity upon irradiation indicates that light 
induces a toxic change in the compound.  It is reasonable sense that compound 
4 would have a greater toxicity upon irradiation, as dppn is known to produce 
singlet oxygen, and to have a long lived excited state.95 
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Table II.1. Cytotoxicity and photocytotoxicity of compounds 1-4 in HeLa cells. 
 
 
 
 
Compilation of Data  
Several compounds in this series have been previously studied,79,94,95 so 
one of the goals was to compile past and current experimental data in an effort 
to fully understand the properties of these compounds that lead to their 
biological activity.  The first dirhodium diimine compounds studied by the Dunbar 
group were [Rh2(O2CCH3)2(phen)2]2+ (1) and  [Rh2(O2CCH3)2(dppz)2]2+ (3).  The 
compound [Rh2(O2CCH3)2(dppn)2]2+ was studied as a part of series 5, shown in 
Figure I.18.  The physical and electronic properties of these compounds have 
been measured, and the relevant information is reported here.  The goal is to 
deduce the effect that the length of aromatic ligand has on the biological activity.  
As the length of the aromatic ligand increases, the metal to ligand charge 
transfer undergoes a general trend of hyperchromicity, and a bathochromic shift 
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Table II.2. Compilation on all LC50 and LC*50 values found for this series. 
 
 
 
 
 
in the MLCT tail.  The λmax for the transitions in this series does not follow a 
noticeable trend.  In an effort to fully understand the effect of the bidentate 
ligands, the results found on the compounds in this series have been compiled 
in several tables (Table II.2, Table II.3, and Table II.4).  Based on the results 
found for compounds 1-4, it can be seen that as the diimine ligand progresses 
from phen to dppn the reduction potentials are increasingly negative.  The 
dirhodium phen derivative is not able to cleave DNA unless an electron acceptor 
is present, while the dppz and dppn derivatives are able to cleave DNA in the 
absence of an electron acceptor.  It was found that the dppn derivative 
sensitizes singlet oxygen (which is known to cleave DNA), but it was still able to 
cleave DNA under anaerobic conditions as well.  The compounds that were 
tested for transcription inhibition were found to inhibit transcription through the 
inhibition of T7RNAP.76,89 
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Table II.3. Experimental data compiled for the dirhodium series, including electronic absorption data. 
 
Table II.4. Cell studies compiled for the dirhodium series. 
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Concluding Remarks 
 Several compounds in this series have been investigated by the Dunbar 
group.  When all of the information is compiled, it is clear that there are some 
promising findings.  Compound 1 is able to inhibit transcription, but it is not 
shown to have phototoxic effects – such as an increase in cytotoxicity upon 
irradiation, or ability to photocleave DNA.  Compounds 3 and 4 exibit the most 
promising results, especially in regards to the potential use as PDT agents.  
Based on all of the information known on this series, it can be proposed that the 
progression from phen to dpq changes the electronic properties of the 
compound.  This is significant because the redox properties of these dirhodium 
diimine compounds affected their anticancer activity.  Although it is still unclear 
where these compounds localize in the cell, and what their targets are. 
 Future work on this series needs to include studes of in cellulo activity of 
these compounds, namely where these compounds are localizing in the cell, 
their effect on biological processes, and the mechanism of cell killing.  Further 
experiments in the Dunbar group are being carried out on this series to improve 
the possibility of these compounds to be used in PDT.  When compared to 
photophrin®, the lead PDT agent on the market, the ratio between LC50 values 
in the dark and light is found to be about 3.5 for the dirhodium compound 
[Rh2(CH3COO)2(dppn)2]2+, and 5 fold for photophrin.  The energy needed to 
induce the increase in toxicity for photophrin is at a λ = 630 nm, whereas the 
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dirhodium compound is irradiated at wavelengths from 400-700 nm, with a 
MLTC shown at 410 nm.  The high energy light needed to activate compounds 1 
through 5 prompted a need to alter the dirhodium series in order to lower the 
energy needed to induce the MLCT, shifting it into the PDT window.   
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CHAPTER III 
ORTHOMETALATED DIRHODIUM PARTIAL PADDLEWHEELS: 
SYNTHESIS AND CYTOTOXICITY STUDIES 
 
Introduction 
 Useful PDT agents are activated by light in the range of 600-850 nm.90  
Dirhodium compounds have shown promising results as potential PDT agents, 
including the derivatives with bidentate diimine (ligands dpq, dppz and dppn).  
There have been several derivatives of the homoleptic diimine series studied in 
an effort to shift the wavelength of the MLCT into the PDT window.  Reducing 
the energy gap between the metal based HOMO and ligand based LUMO can 
be accomplished via several methods, including raising the energy of the 
HOMO.  One way to shift the energy of metal orbitals is by changing the bridging 
ligands on the dirhodium core.84   
The Lewis base strength of the equatorial ligands can be used to control 
the electronic profile of dirhodium compounds.84  There are been many 
examples of dirhodium compounds with various bridging ligands, including those 
of types (N, O), (S, O), (N, S), (N, N), (S, S), (P, O), and (P, C).62  Weak field 
ligands lead to more electrophillic compounds, whereas strong field ligands 
reduce the electrophilicity.84  It is also known that the more electron withdrawing 
bridging ligands of dirhodium compounds are more labile.  An example of this is 
the binding strength of acetate versus trifluoracetate, with the latter being more 
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labile.62  The ability to tune the properties of dirhodium compounds through 
bridging ligands has lead to the investigation of the effect of several types of 
bridging ligands on the anticancer properties of dirhodium compounds.  One that 
was previously mentioned is the mixed paddlewheel compound 
Rh2(DTolF)2(O2CCF3)2, which show similar activity towards Yoshida ascites and 
T8 sarcomas as cisplatin.67   
Orthometalated dirhodium compounds of the types ortho-C and ortho-O-
metalated have been studied for their anticancer properties as well.100  The 
compounds include [Rh2(μ-O2CCH3)2((C6H3-3-OCH3)P(C6H4-3-
OCH3)2)2(O2CCH3)2] – where the methoxyphenylphosphine is bridging through 
carbon and phosphorous (C, P), and [Rh2(μ-O2CCH3)2((C6H4-2-O)P(C6H4-2-
OCH3)2)2(O2CCH3)2] – where the methoxyphenylphosphine is bridging through 
the oxygen of the methoxy group and phosphine atom (O, P).  The ID50 (dose 
needed to inhibit 50% of cellular proliferation) for the cell lines KB (oral 
carcinoma), HU1703 (bladder cancer), SW707 (colon adenocarcinoma), and 
T47D (breast cancer) was investigated.  It was found that the (O, P) derivative 
was the most active, with ID50 values comparable to cisplatin.100 
It has been shown that orthometalated bridging ligands affect the 
dirhodium core, and previous studies indicated that these compounds could 
have significant anticancer activity.100,101  Therefore, it was of interest to use 
diimine derivatives (where the diimine ligand is phen, dpq, dppz, and dppn) of 
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orthometalated tris(p-methoxyphenyl)phosphine (PMP) compounds are toxic 
towards cancer cells, and if they have the potential to be used as PDT agents.  
As previously stated, electron donating ligands reduce the electrophilicity, and 
bond more strongly to the dirhodium core.  This situation could lead to an 
increase in the energy of the HOMO orbital, thereby reducing the energy gap 
between the HOMO and LUMO.   
 
Experimental Section 
Materials 
The reagents tris(p-methoxyphenyl)phosphine (PMP), 1,10 
phenanthroline, 1,2 phenylene diamine, 2,3 diaminonapthalene, and 1,10 
phenanthroline 5,6 dione were purchased from Acros, and used as received.  
The starting material Rh2(μ-O2C2H3)4  was purchased from Pressure Chemicals 
and used as received.  The HeLa cell line was obtained from the American Type 
Culture Collection.   
The starting material 1,10 phenanthroline 5,6 dione was used to 
synthesize the ligands dipyrido[3,2-f:2',3'-h]quinoxaline (dpq),96 
dipyrido[3,2a:2´,3´c]phenazine (dppz),97 benzo[i]dipyrido[3,2-a:2',3'-c]phenazine 
(dppn);98 all according to published procedures. The dirhodium compound 
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Rh2(PMP)2(CH3CO2)2][CH3CO2]2 was synthesized according to published 
procedures.100 
 
Synthesis of [Rh2((C6H3-OCH3)P(C6H3-OCH3)2)2(CH3CN)6][ BF4]2 (5) 
 A sample of (0.050 g,  0.024 M) [Rh2(PMP)2(CH3CO2)2][CH3CO2]2 was 
dissolved in 2 mL of distilled acetonitrile, and (0.012 g) NOBF4 was added in a 
slight excess of a 1:2 ratio.  The solution was stirred in air for two hours at room 
temperature, and then evaporated the solvent under a N2 stream.  The solid was 
washed with diethylether, and then redissolved in 1 mL of acetonitrile.  The 
product was precipitated with 3 mL of diethylether.  The product was recovered 
by filtration in a 67% yield and characterized by 1H NMR spectroscopy (300 
MHz) CD3CN ɗ/ppm (mult./ integral/ assignment): 2.02 (s, 18H, CH3CN) 3.24 (s, 
6H, OMe), 3.71 (s, 6H, OMe), 3.74 (s, 6H, OMe), 6.41 – 7.65 (aromatic region). 
 
Synthesis of [Rh2((C6H3-OCH3)P(C6H3-OCH3)2)2(phen)2][ BF4]2 (6) 
Solid phenanthroline (5.5 mg, 6.10 mM) was added to a solution of (0.020 
g, 3.01 mM) [Rh2((C6H3-OCH3)P(C6H3-OCH3)2)2(CH3CN)6][ BF4]2 in 5 mL of dry 
acetonitrile in an N2 atmosphere.  The mixture was heated to reflux for 24 hours, 
during which time it changed from a purple/brown to bright red color.  At this time 
the solution was cooled to room temperature and diethyl ether was added to the 
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solution to precipitate the product.  The resulting solid was collected by filtration 
and washed with cold acetonitrile.  The reaction afforded a 77% yield. 1H NMR 
(300 MHz) d6-benzene ɗ/ppm (mult./ integral/ assignment): 3.23 (s, 6H, OMe), 
3.70 (s, 6H, OMe), 3.73 (s, 6H, OMe), 6.48 – 7.65 (aromatic PMP) 7.51 (dd, 4H), 
7.62 (s, 4H), 8.18 (m, 4H), 8.39 (d, 4H).   
 
Synthesis of [Rh2((C6H3-OCH3)P(C6H3-OCH3)2)2(dpq)2][ BF4]2 (7) 
Solid dpq (7.10 mg, 6.11 mM) was added to a solution of (0.020 g, 3.01 
mM) [Rh2((C6H3-OCH3)P(C6H3-OCH3)2)2(CH3CN)6][ BF4]2 in 5 mL of dry 
acetonitrile under an N2 atmosphere.  The mixture was heated to reflux for 24 
hours, during which time it changed from purple/brown to a bright red color.  At 
this time the solution was cooled to room temperature, and diethyl ether was 
added to the solution to precipitate the product.  The resulting solid collected by 
filtration and washed with cold acetonitrile.  The reaction afforded an 76% yield. 
1H NMR (300 MHz) d6-benzene ɗ/ppm (mult./ integral/ assignment): 3.22 (s, 6H, 
OMe), 3.68 (s, 6H, OMe), 3.72 (s, 6H, OMe), 6.50 – 7.65 (aromatic PMP) 7.60 
(m, 4H), 8.53 (d, 4H), 8.76 (m, 4H), 8.89 (d, 4H).  
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Synthesis of [Rh2((C6H3-OCH3)P(C6H3-OCH3)2)2(dppz)2][ BF4]2 (8) 
Solid dppz (8.80 mg, 6.19 mM) was added to a solution of (0.020 g, 3.01 
mM) [Rh2((C6H3-OCH3)P(C6H3-OCH3)2)2(CH3CN)6][ BF4]2 in 5 mL of dry 
acetonitrile in an N2 atmosphere.  The mixture was heated to reflux for 24 hours, 
during which time the color changed from purple/brown to a bright red color.  At 
this time the solution was cooled to room temperature, and diethyl ether was 
added to the solution to precipitate the product.  The resulting solid was 
collected by filtration and washed with cold acetonitrile.    The reaction afforded 
an 86% yield. 1H NMR (300 MHz) d6-benzene ɗ/ppm (mult./ integral/ 
assignment): 3.21 (s, 6H, OMe), 3.68 (s, 6H, OMe), 3.71 (s, 6H, OMe), 6.50 – 
7.65 (aromatic PMP) 7.39 (m, 4H), 7.70 (d, 8H), 8.59 (d, 4H), 8.81 (d, 4H).  UV-
vis in H2O λ/nm (ε/M-1cm-1): 362 (10500), 483 (3000), 580 (1300). 
 
Synthesis of [Rh2((C6H3-OCH3)P(C6H3-OCH3)2)2(dppn)2][BF4]2 (9) 
Solid dppn (10.2 mg, 6.10 mM) was added to a solution of (0.020 g, 3.01 
mM) [Rh2((C6H3-OCH3)P(C6H3-OCH3)2)2(CH3CN)6][ BF4]2 in 5 mL of dry 
acetonitrile in an N2 atmosphere.  The mixture was heated to reflux for 24 hours, 
during which time the color changed from purple/brown to a bright red color.  At 
this time the solution was cooled to room temperature, and diethyl ether was 
added to the solution to precipitate the product.  The resulting solid was filtered 
off and washed with cold acetonitrile.  The reaction afforded an 82% yield. 1H 
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NMR (300 MHz) d6-benzene ɗ/ppm (mult./ integral/ assignment): 3.21 (s, 6H, 
OMe), 3.68 (s, 6H, OMe), 3.71 (s, 6H, OMe), 6.50 – 7.65 (aromatic PMP) 7.35 
(dd, 4H), 7.58 (d, 4H), 7.70 (t, 4H), 8.06 (s, 4H), 8.62 (d, 4H), 9.01 (d, 4H).   
 
Instrumentation 
The 1H NMR spectra of the new complexes were recorded on a Varian 
spectrometer at 300 MHz and referenced to the residual proton impurities in the 
deuterated solvents. Absorption measurements of solutions were performed on 
a Shimadzu UV 1601PC spectrophotometer, and 96 well plate measurements 
were performed on a GloMax® Multi Detection System.  
X-ray diffraction data were collected on a Apex II diffractometer equipped 
with a CCD detector.  The data sets were recorded as four ω–scans of 600 
frames each, at 0.3° step width.  The frames were integrated with the Bruker 
SAINT software, and the absorption correction was based on fitting a function to 
the empirical transmission surface as sampled of multiple-measured reflections 
applied by using SADABS. The structures were solved and refined using X-
SEED, a graphical interface to SHELX97.  
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Methods 
X-Ray Structural Study of [Rh2((C6H3-OCH3)P(C6H3-OCH3)2)2(dppz)2][ BF4]2 
 For X-ray crystallographic analysis, a bright red/orange block crystal of 8 
was selected, with approximate dimensions of 0.10 x 0.12 x 0.06 mm3.  The 
crystal was formed spontaneously upon precipitation with diethyl ether from the 
reaction solution in acetonitrile.  The crystal was coated with Paratone oil, and 
transferred to a cold stream (110(2) K) of N2 on a nylon loop.  Indexing of 
preliminary diffraction patterns indicated the crystal was triclinic.  In the final 
cycles of refinement all atoms were refined anisotropically. Hydrogen atoms 
were placed at calculated positions.  The structure was solved and refined in the 
space group P-1. 
 
Cell Culture 
 The HeLa cell line was cultured in Dulbecco’s modified Eagle medium 
with 4.5 mg/mL glucose, and 4 mM L-glutamine (invitrogen), and was modified 
to include 10% fetal bovine serum (Atlanta Biologicals), 50 μg/mL gentamicin.  
Cell cultures were incubated in a humidified atmosphere at 37 °C which 
contained 5% CO2. 
 
 
75 
 
 
In Vitro Cytotoxicity and Photocytotoxicity  
 The LC50 concentrations in HeLa cells of the compounds under 
investigation were determined using the 3-(4,5-dimethylthiazol-2-yl)-d,5-
diphenyltetrazolium bromide (MTT) assay (invitrogen).99  An overconfluent 
(100% confluent) monolayer of cells in sterile 96 well plates was used for this 
experiment.  The cells were plated at a concentration of 24-36 cell/μL – using 
100 μL in each well – and incubated for 48 hours.  Once the cells were 
confluent, the media was replaced with 100 μL of Lebovitz-15 (L15) media 
(containing no phenol red).  The compounds were incubated for 2 hours, and 
then the wells were washed with 1% dibasic phosphate buffer and the 
compound solution was replaced with fresh L15 media.  The plates that were 
used to determine photocytotoxicity were then irradiated for 20 minutes with λirr 
375 nm.  The plates used for cytotoxicity and photocytotoxicity were then placed 
in the incubator until it 24 hours had passed since the time the compounds were 
added.  At this point 10 μL of fresh MTT solution was added to each well.  After 
4 more hours of incubation, 100 μL of fresh SDS solution in 0.01M HCl was 
added to each well.  The plates were incubated for another 4 hours, and then 
the plates were read at 570 nm using a GloMax® Multi Detection System. Each 
experiment contained six wells for one concentration of one compound, and 
each compound was tested three different times. 
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Figure III.1. Synthetic scheme to prepare the series [Rh2(PMP)2(N-N)2]2+. 
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Results and Discussion  
Synthesis and Characterization of the Series [Rh2(PMP)2(N-N)2][CH3CO2]2 
The dirhodium analogues of the “homoleptic series” discussed in chapter 
II: [Rh2(PMP)2(phen)2][BF4]2 (6), [Rh2(PMP)2(dpq)2][BF4]2 (7), 
[Rh2(PMP)2(dppz)2][BF4]2 (8), and [Rh2(PMP)2(dppn)2][BF4]2 (9), were 
synthesized using the starting material [Rh2(PMP)2(CH3CN)2][BF4]2 (5).  
Compound 5 was prepared from the known compound Rh2(PMP)2(CH3CO2)2 
(where PMP is tris(p-methoxyphenyl)phosphine).  The acetate bridging ligands 
were removed by the alkylating agent triethyloxonium tetrafluoroborate 
([(CH3CH2)3O][BF4]) in acetonitrile.  The labile equatorial acetonitrile ligands on 
the compound [Rh2(PMP)2(CH3CN)2][BF4]2 were easily substituted by two 
equivalents of the diimine ligands phen, dpq, dppz, and dppn (compounds 6, 7, 
8, and 9 respectively) upon refluxing for 24 hours (Figure III.1).   
The crystal structure of 8 was determined (Figure III.2), and the bond 
distances and angles are provided (Table III.1 and Table III.2).  The results can 
be compared to the structure of compound 3 (the μ-acetate analogue), to
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determine the effect of the bridging ligand on the structure.  The Rh-Rh bond 
distance of compound 8 is 2.723 Å, and for 3 it is 2.551 Å.  The same splaying of 
the dppz ligands that occurs in 3 is observed in 8, which is attributed to the fact 
that the dppz ligands are brought too close together by the dirhodium bond for 
π-π stacking, and so they splay to reduce the repulsion between them.  The 
compound is similar to the acetate analogue in that there is internal twist, 
breaking away from an eclipsed conformation in an attempt to reduce repulsive 
interactions.94   
 
Table III.1. Crystal data and structure refinement for compound 8. 
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Table III.2. Bond distances for [Rh2(PMP)2(dppz)2][BF4]2. 
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Table III.3. Dihedral angle for the structure of [Rh2(PMP)2(dppz)2][BF4]2. 
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Figure III.2. X-ray crystal structure of [Rh2(PMP)2(dppz)2][BF4]2. 
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This series was also characterized by 1H NMR spectroscopy (Figure 
III.3).  In the spectra there is an upfield shift in some of the proton resonances in 
the aromatic region as compared to the dirhodium acetate analogues.  This 
could be caused by an increase in shielding due to the stronger trans effect of 
the orthometalated phosphine ligand.  This theory is further corroborated by the 
bond distances seen in the crystal structure.102  The Rh-N bond distance 
between the rhodium and the nitrogen of dppz for compound 3 is approximately 
2.00 Å, whereas the corresponding bond distance in 8 is approximately 2.10 Å.  
Elongation of the Rh-N bond is evidence of the trans effect, and explains the 
upfield shift in the dppz resonances for compound 8.  The downfield shift in the 
aromatic resonances of the PMP ligand as compared to the known structure 
Rh2(PMP)2(CH3CO2)2 is also observed.  The electronic absorption spectrum for 
8 was found in pH 7 tris buffer.  It is seen that there is a strong absorption at 
wavelengths lower than 400 nm.  The tail of the lowest energy band tails off 
above 600.  This represents a bathochromic shift as compared to the acetate 
analogue, compound 3, which has a metal centered band at about 560 nm. 
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Figure III.3. 1H NMR spectrum of [Rh2(PMP)2(dppz)2][BF4]2. 
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Cytotoxicity and Photocytotoxicity 
The cytotoxicity and photocytotoxicity of compounds 5, 6, 7, 8, and 9 
were determined using the MTT assay and the LC50 of the compounds were 
determined in the dark and after irradiation.  The range of concentrations used in 
the assay for compounds 5, 6, 7, 8, and 9 were 50 μM to 800 μM; 
concentrations that are based on the results of previous series.  For all of the 
MTT assays, both in light and in the dark, the amount of ambient light was 
limited as much as possible, and experiments used to determine the 
photocytotoxicity exposed the cells to light for 20 minutes.  The results are 
summarized in Table III.3.   
It can be seen that compounds 7 and 9 are the most cytotoxic in the dark, 
while compound 8 is the least cytotoxic in the dark.  The extreme difference in 
the progression of cytotoxicity from the dpq (7) to dppz (8) to dppn (9) 
derivatives is surprising, but when considering the properties of the compounds, 
it seems plausible.  The solubility of the compounds in aqueous solutions 
dramatically decreases from dpq to dppz, which may reduce the cytotoxic effects 
of dppz to dppn.  However the dppn compound is very cytotoxic in the dark, 
which could be caused by the redox properties of the compound.  The 
photocytotoxicity could lend some further insight into this.  
The toxicities of 5, 6, 7, 8, and 9 were determined after irradiation with 
light for 20 minutes.  Compound 9 has an LC*50 of 71 ± 3 μM, which is very 
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close to its LC50 value in the dark (85 ± 5 μM).  The ratio of LC50 values in the 
dark and light is 1.2, which indicates that irradiating the compound for 20 
minutes does not cause an increase in cytotoxicity.  It is known that dppn 
compounds (such as compound 4) are able to produce singlet oxygen, and 
photocleave DNA in the presence and absence of oxygen upon irradiation with 
light.  Therefore, it could be that the redox activity of this compound seen upon 
irradiation of compound 4 readily occurs in the dark for compound 9.  In order to 
conclusively determine the mechanism of cytotoxicity for 9 more experimentation 
is needed; including electrochemistry experiments and further analysis of 
photoactivity.   
The photocytotoxicity of 7 and 8 show an increase in toxicity upon 
irradiation with light.  Compound 7 has a two fold increase in cytotoxicity in the 
dark and light upon irradiation.  Compound 8 has an LC50 value of 901 ± 6 μM, 
and an LC*50 value of 126 ± 6 μM; which is a 7 fold increase in cytotoxicity.  This 
is a better ratio than that found in photofrin®, indicating that this compound has 
the potential to be used as a PDT agent.   
Compounds 5 and 6 have not yet been discussed.  Neither of these 
compounds shows an increase in toxicity upon irradiation.  The LC50 values are 
greater than the other compounds in the series, with 5 being around 250 μM and 
6 being just under 600 μM.  The results for 6 are expected, based on the results 
found for compound 2 in the previous chapter.  Both of these dirhodium phen 
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derivatives have high LC50 values, with the LC50 in the dark having a slightly 
higher toxicity than the LC*50 value.  The results of compound 5 are somewhat 
surprising because it is known that the acetonitrile ligands in both the axial and 
equatorial ligands are labile, especially upon irradiation.  It is possible that the 
compound is not able to easily enter the cell, or perhaps the less electrophilic 
dirhodium core is not as active without an aromatic ligand that is capable of 
being easily reduced. 
One of the reasons for studying this series of compounds was to see how 
the bridging ligand affects the biological properties of the compound.  When 
comparing the cytotoxicity and photocytotoxicity of these compounds it is clear 
that the PMP bridging ligand enhances the toxicity of compounds 7 and 9 in the 
dark and upon irradiation.  The cytotoxicity in the dark for compound 8 is 
dramatically lower than that of 3, and has exactly the same photocytotoxicity as 
compound 3 (Table III.4).  This indicates the mechanism of activity upon 
irradiation is similar for both compounds and so is likely to be due to the dppz 
ligand.  More work needs to be done to truly understand the results found. 
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Table III.4. Cytotoxicity and photocytotoxicity data for compounds 5-9. 
 
 
 
Concluding Remarks 
 The results found from these experiments represent promising steps 
forward in the pursuit of understanding the structure-function relationship of 
dirhodium compounds, and the pursuit of discovering potential PDT agents.  The 
ratio of cytotoxicity in the dark and upon irradiation for compound 8 makes it a 
good candidate for PDT.  The 7-fold increase in toxicity is a higher ratio than the 
5.5 fold increase observed in the clinical PDT agent photofrin®.  It should be 
noted, however, that 8 was irradiated at a wavelength of 350 nm, where it 
absorbs strongly.  Further studies need to be done to determine the ratio of 
toxicity upon irradiation with light in the PDT window (greater than 600 nm). 
 It is interesting to observe the effect that changing the bridging ligand had 
on the homoleptic dirhodium diimine series.  Compounds 6-9 had similar or 
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higher toxicity than their counterparts (1-4), and a slight bathochromic shift in the 
tail of the MC band observed in the electronic absorption spectrum.  In the cell 
studies detailed in the introduction to this chapter an orthometalated bridging 
ligand bound through an oxygen atom showed greater cytotoxicity than the 
ortho-c analogue.  It should be mentioned that the preliminary studies of the 
cytotoxicity and photocytotoxicity of a known ortho-o dirhodium compound, 
[Rh2(O2CCF3)3(TMPP)] (where TMPP is (2,4,6-trimethoxyphenyl)phosphine), 
was examined for anticancer activity.103  However, there was no change in 
cytotoxicity upon irradiation, and the LC50 concentrations were almost 500 μM.  
This is likely due to the poor solubility of the compounds in water, thus further 
efforts in developing more water soluble analogues is of high interest. 
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CHAPTER IV 
SYNTHESIS, CHARACTERIZATION, AND BIOLOGICAL PROPERTIES OF 
[Ir2(DTolF)2(CH3CN)6][BF4]2 
 
Introduction 
 Iridium compounds have been gaining in popularity for use as anticancer 
drugs.104  Research into the biological propterties of iridium compounds have 
focused on Ir(III) and Ir(I) oxidation states to date.104,105,106  A primary area of 
interest has been iridium(III) compounds with diimine ligands that are able to 
intercalate between DNA base pairs.107  In 2001, Barton and coworkers showed 
that Ir(III) phi complexes were capable of intercalating DNA.92,108  The negative 
reduction potential of [Ir(bpy)(phen)(phi)]3+ made it possible to investigate the 
properties of the reduced phi complexes intercalated in DNA without interference 
from Ir =(II) (where phi is 9,10-phenanthrenequinone diimine).108   
Other known Ir(III) intercalators include [Ir(ppy)2(pp)][PF6] (where ppy is 2-
phenylpyridine, and pp is dpq, dppz, or dppn),109  [(η5-C5Me5)Ir(dppz)(peptide-
κS)]n+,110 and [(η5-C5Me5)IrCl(pp)][CF3SO3] and  [(η5-
C5Me5)Ir((NR2)2CS)pp][CF3SO3]2 (where R is H or Me, and pp is dpq, dppz, or 
dppn).104  The compound [Ir(ppy)2(pp)][PF6] was studied for its luminescent 
properties in the presence and absence of DNA; revealing that the luminescence 
of the compounds intercalated in DNA can be up to 40 times greater (depending 
on the analogue) than the luminescence of the compound in aqueous media.109  
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The increase in luminescence of the iridium(III) compound in the presence of 
DNA is due to the fact that the luminescence is ligand-based, and when the 
compound is able to hydrogen bond, it decreases the luminescence, but when 
the ligand intercalates into DNA it is protected from any interactions with water.  
Upon intercalation the diimine ligand is in a more hydrophobic and rigid 
environment, which also helps to increase the luminescent properties.109  The 
half sandwich Ir(III) compound, [(η5-C5Me5)Ir(dppz)(peptide-κS)]n+, was found to 
bind DNA through intercalation with Kb values of 1.3 - 3.3 X 106.107  It was also 
observed that the peptide was eventually cleaved, leaving the iridium core to 
bind to DNA.  This same research later published work on the other half 
sandwich compounds listed above, [(η5-C5Me5)Ir(L)(pp)][CF3SO3]x (where L is 
Cl, (NH2)2CS, and (N(CH3)2)2CS).104  The analogue where L = Cl was shown to 
intercalate DNA, and the slow substitution of the chloride ligand results in the 
iridium(III) center binding to N7 on the DNA.  In the thiourea derivative, sterics 
lead to side-on intercalation of dppz, and partial intercalation of dpq; however, 
dppn is too large to intercalate in any manner.  The tetramethylthiourea 
derivative shows strong binding of the dppn derivative to DNA via intercalation, 
which is in opposition to the results shown for the thiourea compound.  This fact 
is thought to be caused by the tetramethylthiourea compound to change the 
conformation of DNA from B to A.104   
Iridium(III) partial sandwich compounds have recently been investigated 
for potential cytotoxicity towards cancer cells.106  In 2010, the compound [(η5-
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C5Me5)Ir(pyTz)Cl]+ (where pyTz is 2-(pyridine-2-yl)thiazole) was tested in the 
ovarian cancer cell lines A2780 and A2780cisR (A2780cisR being cisplatin 
resistant).111  The IC50 (the concentration required to inhibit 50%) for the 
iridium(III) compound exibits greater than 300 μM after 72 hours, showing that it 
was not very cytotoxic.  Its rhodium (III) counterpart had similar cytotoxicity 
values after 72 hours of exposure.111   
Another partial sandwich compound, [(η5-C5Me5)IrCl(XY)]n (where XY is 
either 2,2’-bipyridine – n is 1+, or 2-phenylpyridine – n is 0), has been probed for 
its anticancer activity.112  The bidentate ligand, XY, was shown to greatly affect 
the IC50 value.  When introduced to the A2780 cell line for 24 hours, the bpy 
derivative has an IC50 value greater than 100 μM, whereas the phpy derivative 
has an IC50 value of about 11 μM.  These compounds can also undergo 
substituting of the chloride ligand for 9-ethylguanine, or 9-methyladenine.  It was 
shown that the bidentate ligand used affects the equalibrium of binding of 9-EtG 
or 9-MeA, where the bpy derivative binds to only 9-EtG, and the phpy derivate 
binds both bases, but it binds 9-MeA more strongly.  This is an excellent 
example of how the chelating ligands affect the anticancer properties of Iridium 
(III) compounds.112   
Recently, more work has been carried out to determine the effect that the 
bidentate ligand has on the cytotoxicity of iridium (III) half sandwich compounds.  
To this end a series of compounds, [(η5-C5Me5)IrCl(phen*)]+ (where phen* is 5,6-
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methylphen, 5-Clphen, or 5-NO2phen), has been studied.104  It was shown that 
the more electron withdrawing the phen derivative is, the more cytotoxic the 
compound is.  The cytotoxicity was found for several cell lines, including MCF-7 
(breast cancer), HT-29 (colon cancer), and immortalized HEK-293, when the 
cells were incubated with the compounds for 48 hours.  For all cell lines, the 5,6-
methylphen derivative was the least cytotoxic derivative (with IC50 values 
between 50 and 60 μM), and the 5-Clphen and 5-NO2phen were about half as 
cytotoxic.  The ability to drastically tune the cytotoxicity iridium (III) compounds 
based on the ligand field lends great potential for designing anticancer drugs.104   
In addition to Ir(III) compounds, Ir(I) compounds have been shown to 
have anticancer activity as well.105  However, few, if any, examples of iridium (II) 
compounds have been investigated for their biological activities.  More 
specifically, diiridium (II,II) compounds have not been studied as anticancer 
agents, but the redox properties of these compounds are proving to be useful in 
photocatalytic H2 production, photochemistry, bond activation, and other 
chemistry.113  The first examples of diiridium (II,II) compounds were reported in 
the 1970’s and 80’s.114,115  The exploration of the properties of diiridium 
compounds have been compared to the better understood properties of 
dirhodium compounds.  In comparison the diiridium sigma bond is stronger than 
its dirhodium counterpart, and it was found that similarly to dirhodium, the axial 
ligands do not greatly affect the iridium-iridium bond distance.116 
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The reactivity, and properties of diiridium (II,II) compounds are still less 
known than dirhodium (II,II) compounds, which is understandable as diiridium 
(II,II) compounds are very stable, and therefore tend to be relatively inert.117  
Taking a cue from dirhodium chemistry, we decided to synthesize diiridium 
compounds with more labile ligands, such as acetonitrile.  In this vein the 
compound [Ir2(DTolF)2(CH3CN)6][BF4]2 was synthesized.117  The Ir-Ir bond 
distance is 2.601(1) Å, the equatorial Ir-NCCH3 bond distance is approximately 
2.00 Å, and the axial Ir-NCCH3 bond distance is approximately 2.20 Å.117  As 
compared to the dirhodium analogue that was reported a few years later, 
[Rh2(DTolF)2(CH3CN)6][BF4]2, the Rh-Rh bond distance is 2.5594(8) Å, the 
equatorial Rh-NCCH3 bond distance is approximately 2.02 Å, and the axial Rh-
NCCH3 bond distance is about 2.23 Å.117-119  While the dirhodium bond distance 
is shorter than that of the diiridium compound, the metal-NCCH3 bond distances 
are shorter for the diiridium compound than the dirhodium compound.   
The compound [Rh2(DTolF)2(CH3CN)6][BF4]2 was later investigated for 
biological activity, and was found to bind dsDNA in its equatorial 
positions.73,74,120  Because of this result it was of interest to study the biological 
activity of the compound [Ir2(DTolF)2(CH3CN)6][BF4]2.  This chapter details new 
synthetic routes to the diiridium partially solvated compound, and 
characterization of the structure.  The cytotoxicity and the photocytotoxicity in 
HeLa cells was studied; the partition coefficient was found to lend insight into a 
possible contributor the toxicity of the compound. 
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Experimental Section 
Materials 
The reagents NOBF4, p-toluidine, triethyl orthoformate, and 
cyclooctadiene (COD) were purchased from Acros, and used as received.  The 
starting material [Ir(COD)Cl]2 was purchased from Pressure Chemicals and used 
as received.  The HeLa cell line was obtained from the American Type Culture 
Collection.   
The starting materials ditolylformamidinate and [Ir(DTolF)COD]2 (where 
DTolF is formamidine and COD is 1,8-cyclooctadiene) were synthesized 
according to literature procedures.121,122   
 
Synthesis of [(DTolF)2Ir(COD)Ir(CH3CN)3][BF4]2 (10) 
The oxidizing agent NOBF4 (0.022 g) was added to a solution of (0.100 g) 
[Ir(DTolF)COD]2 in 8 mL of distilled acetonitrile under an N2 atmosphere.  The 
mixture was stirred for 24 hours, during which time the color turned from 
purple/brown to brown.  The solution was reduced in volume, and diethylether 
was added to precipitate the product.  The reaction afforded a 92% yield. 1H 
NMR (300 MHz) CD3CN ɗ/ppm (mult./ integral/ assignment): 1.96 (s, free 
acetonitrile), 2.32 (s, 24H), 2.50 (s, 10H, H2O), 2.70 (s, 3H) 2.81 (s, 8H), 4.75 (s, 
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2H), 5.2 (s, 2H), 6.92 (t, 5H), 7.05 (m, 6H), 7.17 (m, 9H), 7.28 (s broad, 4H), 
7.90 (s, 2H). 
 
Synthesis of [Ir2(DTolF)2(CH3CN)6][BF4]2 (11) 
 The compound [(DTolF)2Ir(COD)Ir(CH3CN)3][BF4]2 (0.061 g) was refluxed 
in 10 mL of acetonitrile under an N2 atmosphere for 2 hours, and then the 
reaction was stirred under N2 overnight at room temperature.  The solvent was 
reduced in volume to about 4 mL under vacuum, and a small amount of NaBF4 
was added to help precipitate the product.  Diethyl ether was then added to 
precipitate the product, and it was left at 5 °C overnight.  The product was 
collected by filtration in air, and 84% was recovered.  1H NMR (300 MHz) 
CD3CN ɗ/ppm (mult./ integral/ assignment): 1.96 (s, free acetonitrile), 2.26 (s, 
6H, tolyl), 2.72 (s, 12H, MeCN), 6.93 (d, 8H) 7.02 (d, 8H), 7.75 (s, 2H). 
 
Instrumentation 
The 1H NMR spectra of the new complexes were recorded on a Varian 
spectrometer at 300 MHz and referenced to the residual proton impurities in the 
deuterated solvents. Absorption measurements of solutions were performed on 
a Shimadzu UV 1601PC spectrophotometer, and 96 well plate measurements 
were performed on a GloMax® Multi Detection System.  Mass spectra were 
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acquired on a PE SCIEX QSTAR Pulsar electrospray ionization mass 
spectrometer at Texas A & M University. 
 
Methods 
Cell Culture 
 The HeLa cell line was cultured in Dulbecco’s modified Eagle medium 
with 4.5 mg/mL glucose, and 4 mM L-glutamine (Invitrogen), and was modified 
to include 10% fetal bovine serum (Atlanta Biologicals), 50 μg/mL gentamicin.  
Cell cultures were incubated in a humidified atmosphere at 37 °C which 
contained 5% CO2. 
 
In Vitro Cytotoxicity and Photocytotoxicity  
 The LC50 concentrations in HeLa cells of the compounds under 
investigation were determined using the 3-(4,5-dimethylthiazol-2-yl)-d,5-
diphenyltetrazolium bromide (MTT) assay (Invitrogen).99  An overconfluent 
(100% confluent) monolayer of cells in sterile 96 well plates was used for this 
experiment.  The cells were plated at a concentration of 24-36 cell/μL – using 
100 μL in each well – and incubated for 48 hours.  Once the cells were confluent 
the media was replaced with 100 μL of Lebovitz-15 (L15) media (containing no 
phenol red).  The compounds were incubated for 2 hours, and then the wells 
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were washed with 1% dibasic phosphate buffer and the compound solution was 
replaced with fresh L15 media.  The plates that were used to determine 
photocytotoxicity were then irradiated for 20 minutes with λirr 350 nm.  The plates 
used for cytotoxicity and photocytotoxicity were then placed in the incubator until 
it 24 hours had passed since the time the compounds were added.  After this 
time 10 μL of fresh MTT solution was added to each well.  After 4 additional 
hours of incubation, 100 μL of fresh SDS solution in 0.01M HCl was added to 
each well.  The plates were incubated for another 4 hours, and then the plates 
were read at 570 nm using a GloMax® Multi Detection System. Each experiment 
contained six wells for one concentration of one compound, and each compound 
was tested three different times. 
 
Results and Discussion 
Synthesis and Characterization of [Ir2(DTolF)2(CH3CN)6][BF4]2  
The synthesis and characterization of [Ir2(DTolF)2(COD)(CH3CN)3][BF4]2 and 
[Ir2(DTolF)2(CH3CN)6][BF4]2 were first reported by Dunbar and coworkers in 
1995.  After examining the anticancer effects of various dirhodium series of 
compounds we were interested in determining the anticancer activity of 
analogous diiridium compounds.  In pursuit of this goal a problem was 
encountered, namely that color of [Ir2(DTolF)2(CH3CN)6][BF4]2 would change 
from a pale yellow to a dark purple/grey when exposed to light over a short 
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period of time.  The best hypothesis for this occurrence is that the silver (in the 
silver trifluoroacetate required to synthesize the precursor for this compound) 
was not fully removed.  In order to test the toxicity of these compounds, and be 
sure that silver did not interfere in the results it was necessary to find an 
alternate synthesis that did not require silver (Figure IV.1). 
 In the original synthesis the compound [Ir(DTolF)(COD)]2 was reacted 
with silver trifluoroacetate in toluene.  The silver acts as an oxidizing agent, 
forming the mixed valence iridium (I,III) compound, 
[(DTolF)2Ir(COD)Ir(CF3COO)2(H2O)].  This compound is then refluxed for three 
hours in acetonitrile (using Schlenk-line techniques) to first form the intermediate 
[Ir2(DTolF)2(COD)(CH3CN)3][BF4]2.  After three more hours of refluxing the 
hexaacetonitrile compound, [Ir2(DTolF)2(CH3CN)6][BF4]2, is formed.  In several 
instances it was found that the product degraded in light.  The obvious cause for 
this would be silver contamination, and an effort was made to find evidence for 
this hypothesis.  The ESI mass spectra of the freshly made pale yellow 
[Ir2(DTolF)2(CH3CN)6][BF4]2 + H+ at m/z is 1081.  Upon turning to a purple/brown 
color the ESI mass spec was performed on the same batch of 
[Ir2(DTolF)2(CH3CN)6][BF4]2 + H+ and the m/z was 1051.  Efforts to find the 
identity of the species formed using 1H NMR are still underway.   
In order to circumvent the use of silver, another oxidizing agent needs to 
be used.  Because the mixed valence compound is not necessary, a one step 
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reaction from [Ir(DTolF)(COD)]2 to [Ir2(DTolF)2(CH3CN)6][BF4]2 was attempted in 
acetonitrile using two equivalents of the oxidizing agent NOBF4.  This oxidizing 
agent was chosen in hopes that it would not coordinate to the iridium compound.  
It was found that upon reacting [Ir(DTolF)(COD)]2 with NOBF4 in acetonitrile at 
room temperature, the compound [Ir2(DTolF)2(COD)(CH3CN)3][BF4]2 was 
formed.  When refluxing this compound in acetonitrile, the partially solvated 
compound was successfully prepared.   
The identities of the compounds [Ir2(DTolF)2(COD)(CH3CN)3][BF4]2 
(Figure IV.2) and [Ir2(DTolF)2(CH3CN)6][BF4]2 (Figure IV.3) were confirmed via 
1H NMR spectroscopy, and mass spectrometry.  From the 1H NMR spectrum of 
[Ir2(DTolF)2(CH3CN)6][BF4]2 it can be seen that there is a peak at 7.75 ppm and 
7.02 to 6.96 ppm, which is indicative of the formamidinate bridge-head and 
aromatic region (respectively).117  The ESI mass specrum of the hexaacetonitrile 
compound has a peak at m/z 1081, which indicates that the axial acetonitrile 
ligands remain intact.  As previously stated, Ir-Ir bond distance is 2.601(1) Å, the 
equatorial Ir-NCCH3 bond distance is approximately 2.00 Å, and the axial Ir-
NCCH3 bond distance is approximately 2.20 Å.  As compared to the dirhodium 
analogue of this compound, the Ir-N bond distances are shorter, which indicates 
a strong interaction.   
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Figure IV.1. A) Reported synthesis for [Ir2(DTolF)2(CH3CN)6][BF4]2  B) New synthesis of 
[Ir2(DTolF)2(CH3CN)6][BF4]2   
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Figure IV.2. 1H NMR spectrum of (COD)Ir(DTolF)2Ir(CH3CN)3. 
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Figure IV.3. 1H NMR spectrum of [Ir2(DTolF)2(CH3CN)6][BF4]2. 
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Cytotoxicity and Photocytotoxicity 
 
Table IV.1. Cytotoxicity and photocytotoxicity of [Ir2(DTolF)2(CH3CN)6][BF4]2. 
 
The cytotoxicity and photocytotoxicity of [Ir2(DTolF)2(CH3CN)6][BF4]2 was 
determined in HeLa cells (Table IV.1).  The cytotoxicity was determined to be 83 
± 4 μM and the photocytotoxicity was determined to be 105 ± 9  μM.  These 
values were found after an incubation period of 2 hours.  The LC50 value (in the 
dark) after incubation of HeLa cells with the partially solvated compound for 24 
hours is 54 ± 4 μM.  The low LC50 values are somewhat surprising based on the 
stability of the diiridium compound, and its full coordination sphere.  In the 
dirhodium series studied it was proven that the toxicity of the compounds was 
related to having an open axial position that could bind to biomolecules.123  The 
importance of the axial position to dirhodium toxicity was shown when the LC50 
values of a series of compounds were studied.  The series is composed of 
[Rh2(CH3CO2)2(np)2]2+ (where np is 1,8-naphthyridine), [Rh2(CH3CO2)2(np)2]2+ 
(where pynp is 2-(2-pyridil)1,8-naphthyridine), and [Rh2(CH3CO2)2(pynp)2]2+.  It 
was shown that when both of the axial positions were blocked the compound is 
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not cytotoxic, meaning that the compounds were not capable of binding to DNA, 
and the LC50 values were above 500 μM (which is considered to be non-
toxic).123   
 This hypothesis was carried over into the diiridium chemistry, but these 
results called that assumption into question.  Because of the evidence seen in 
the mass specrum it was assumed that the axial acetonitrile were inert to 
substitution.  However, a color change from pale yellow to purple/brown was 
observed when the compound was dissolved in octanol.  Further studies showed 
that the diiridium partially solvated compound was dark purple in acetone, green 
in glycerol, and bright yellow in DMSO (dimethylsulfoxide).  When the diiridium 
compound is dissolved in acetone, only a small quantity of acetonitrile will cause 
the solution to return to a pale yellow.  These observations call into question the 
idea that the axial ligands would not be displaced.  To test this concept even 
further the solubility and color change of [Ir2(DTolF)2(CH3CN)4(CNCH3)2][BF4]2  
was tested in octanol and acetone.  This compound is known to have very 
strongly bound isonitrile ligands, which will not be displaced easily.  When 
dissolved in both octanol and acetone a decrease in solubility was observed as 
compared to compound 11, and there was no color change.  These results 
indicate that it is likely the axial positions of 11 that are labile, and therefore are 
able to interact with biomolecules in vivo.  This could be the reason for the high 
cytotoxicity of compound 11. 
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Concluding Remarks 
 Iridium compounds are not well studied, but more emphasis is being 
placed on research into iridium (III) partial sandwich compounds.  There are few, 
if any, reports on the biological activity of diiridium (II,II) compounds, and so this 
is an important study.  The findings that this inorganic diiridium compound has a 
high cytotoxicity that is independent of photoactivation opens the door to further 
studies of diiridium compounds.  It is even more interesting that this is a very 
stable compound, and yet has a low LC50 concentration.   
The success of the silver-free synthesis is also relevant, as diiridium (II,II) 
compounds are be difficult to work with.  The partially solvated diiridium 
compound was originally of interest because of an effort to make another 
homoleptic diimine series with a different metal.  The substitution of the 
equatorial acetonitrile ligands has proven very difficult.  Even after refluxing for 
over 5 days, there is no substitution observed.  The diimine series is still being 
actively pursued, as it has been observed for iridium (III) compounds that the 
diimine derivatives can be very active.  It will be exciting to see how this will 
translate to the diiridium (II,II) compounds. 
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CHAPTER V 
CONCLUSIONS 
 
 This thesis details the synthesis, cytotoxicity, and photocytotoxicity of 
rhodium and iridium metal-metal bonded compounds.  The diimine ligands used 
in the dirhodium compounds (dpq, dppz, and dppn) exibit cytotoxic behavior 
when irradiated with light.  The most interesting compounds are the dppz and 
dppn derivatives, which have the highest ratio between the LC50 values in the 
dark and upon irradiation.  Further exploration in this area is needed to 
understand the cellular targets of these compounds, and their mechanism of 
cytotoxicity.  Previous results have shown that compound 4 is not capable of 
reaching the nucleus, and kills the cell via a non-programmed cell death 
pathway.  The next step for determining the cellular localization of compounds 
would be to tag the compounds with a fluorescent dye, or use ICP mass 
spectroscopy to see if the compounds enter the nucleus.  If these experiments 
could be repeated over a period of time it would be possible to see how long it 
takes the drugs to reach their target. 
 The series of compounds 1-4 are of interest as potential PDT agents.  
The best candidates for this therapy are compounds 3 and 4, which exhibit an 
increase in cytotoxicity upon irradiation with 350 nm light.  This is not the optimal 
wavelength for use in PDT therapy, and in an attempt to shift the energy of light 
needed to activate the compound to a lower energy, different bridging ligands 
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are being explored.  This thesis details the synthesis of a completely new series 
of compounds 5-9.  When the electronic absorption spectrum was measured, a 
bathochromic shift in the tail of the MC band into the PDT window is seen.  That 
coupled with the 7-fold increase in cytotoxicity between the dark and the light for 
compound 8 makes it a potential PDT agent.  Further studies need to be 
performed on the photoactivity of the compound to test if it is capable of 
sensitizing singlet oxygen.  Also, DNA cleavage studies in the dark and upon 
irradiation would indicate the ability of this compound to cleave DNA.  These 
studies can be performed in a low oxygen environment, which would reveal the 
ability of these compounds to be toxic without producing singlet oxygen (this is a 
character of the series 1-4).  Many of the most aggressive tumor cells are 
hypoxic, making this a desirable trait in a PDT agent.   
 Future work will focus on new bridging ligands that could further improve 
the potential for these dirhodium diimine compounds to be used as PDT agents.  
Further studies of ortho metalated compounds (bound through oxygen and 
phosphorous atoms) would be a good series to study.  While the TMPP ligand 
was not immediately successful, perhaps a more water soluble version would 
prove valuable.  It would also be interesting to investigate how the bridging 
ligand effects the localization and mechanism of cell death in the cell.   
 Finally, the diiridium project proved to be the most challenging, but the 
most rewarding.  The new synthetic path to compound 11 will prove useful in 
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using any of its derivatives in biological studies.  It should also be noted that the 
new synthetic pathway eliminates a step from the synthetic process, which is 
advantageous.  Future work will also focus on the substitution of the acetonitrile 
ligands for the diimine ligands (phen, dpq, dppz, and dppn).   
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